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ABSTRACT 
 
Acute inflammatory kidney diseases may resolve, leaving limited residual 
damage or progress to cause chronic renal scarring characterized by glomerulosclerosis 
and interstitial fibrosis. Understanding the mechanisms that control inflammation within 
the kidney may facilitate the development of treatment strategies to prevent irreversible 
kidney damage and slow progression of chronic kidney disease. Infiltration of 
mononuclear cells is recognized as an early event in many different conditions that may 
ultimately lead to kidney injury. Having extravasated from blood vessels at sites of 
injury, these multifunctional cells differentiate into tissue macrophages, which 
depending on their phenotype, have the potential to both promote resolution of 
inflammation or to cause scarring, making them an attractive target for therapy. Having 
left the glomerular capillary lumen, mononuclear cells are very likely to encounter the 
mesangial matrix. It was therefore hypothesized that interactions between monocytes 
and matrix components might modify the behavior of the infiltrating cells and thereby 
modify the outcome of the inflammatory process.  
The work presented in this thesis demonstrates that mesangial matrix activates 
monocytes leading to expression of peroxisome proliferators activated receptor γ and the 
CD36 scavenger receptor, both markers of macrophage differentiation. Since LDL 
accumulation in the mesangium may contribute to glomerular injury, the interaction 
between this lipoprotein and the matrix was also examined. These studies demonstrated 
that LDL becomes oxidized when exposed to matrix components, possibly due to loss of 
protective antioxidants. The presence of oxidized LDL has the potential to induce 
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mesangial cell chemokine production, which is likely to promote further monocyte 
influx into the glomerulus. Furthermore, matrix-activated monocytes internalized 
oxidized LDL via CD36 scavenger receptor, leading to foam cell formation, a 
recognized characteristic feature of glomerular injury. Foam cell formation may in turn 
amplify and perpetuate the disease process by driving further production of cytokines 
and growth factors.  
Finally, to establish that these observations were relevant to human glomerular 
disease, the presence of macrophages expressing PPAR-γ and the CD36 scavenger 
receptor in human kidney biopsy samples taken from patients with inflammatory 
glomerular disease was demonstrated, using sections from non-inflamed kidneys as 
controls. These observations imply that monocyte-matrix interactions are important in 
the context of glomerular disease and may represent a potential target for therapies 
designed to limit injury resulting from glomerular inflammation.  
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Glomeruli are susceptible to a variety of inflammatory, metabolic, haemodynamic, 
toxic and infectious insults which induce similar clinicopathologic presentations. 
Despite advances in understanding the factors that initiate glomerular injury, efforts to 
stop or slow the progression of established chronic renal disease have proved largely 
unsuccessful. The fact that multiple pathogenic mechanisms result in a similar 
histological endpoint suggests that the glomerulus has only a limited repertoire of 
responses to injury and that renal scarring can be considered to represent a secondary 
phenomenon rather than a specific disease process. Glomerulosclerosis is the final result 
of a number of interrelated events leading to permanent glomerular injury. Histological 
features of many chronic progressive renal diseases are evidenced by the accumulation 
of matrix, macrophages and cholesterol in sclerotic glomeruli. Several factors act 
independently or together to play a pivotal role in determining whether the final outcome 
of an acute inflammatory glomerular lesion leads to complete resolution or permanent 
scarring. The study of these factors may suggest new targets for therapeutic intervention. 
 
1.1. THE NORMAL GLOMERULUS 
 
Blood enters the glomerulus through the afferent arteriole, which branches into 
tiny clusters of looping blood vessels, which comprise the glomerular (“capillary”) tuft 
(which is actually a highly specialized section of an arteriole). As blood passes through 
the tuft, the plasma is filtered through fenestrations in the endothelial cells and the 
glomerular basement membrane (GBM), then through spaces between the podocyte foot 
processes (in the slit membrane) into Bowman’s space. The capillary endothelium, GBM 
and the slit membrane constitute the filtration barrier that collectively filters plasma 
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allowing passage of water, small solutes such as sodium, urea, and glucose, small 
proteins and small organic molecules. The filtered blood is then drained from the 
glomerular tuft through the efferent arteriole. The GBM is continuous throughout the 
glomerulus, surrounding each capillary loop and the ‘stalk’ region of the glomerular tuft. 
At the vascular pole, the GBM is continuous with Bowman’s capsule. Between the 
glomerular capillaries lie the mesangial cells and the mesangial matrix, which together 
provide structural support by surrounding the glomerular capillaries (Figure 1.1a and 
1.1b). Some mesangial cells are located outside the glomerulus, between the afferent and 
efferent arterioles and are known as Lacis or Goormaghtigh cells.  
 
Figure 1.1a. The Normal Glomerulus  
 
(Image courtesy of PB Works nephrology images) 
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Figure 1.1b. Schematic Diagram of a Single Capillary Tuft within Bowman’s 
Capsule 
 
 
 
Much of the original work describing the mesangium was concerned with the 
ultra-structural appearance of cross-sections of the glomerulus using electron and light 
microscopy. According to current understanding, the mesangium consists of mesangial 
cells and mesangial cell matrix, which are capable of various tasks Table 1.1. The 
interstitial areas of each lobule join at the glomerular stalk and are thereby in direct 
continuity with the renin-secreting juxtaglomerular apparatus. 
 
(Image courtesy of PB Works nephrology images) 
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Table 1.1. Functions of the Glomerular Mesangium 
The table below gives a summary of the various functions of the Mesangial cell and 
Mesangial cell matrix within the mesangium, as reviewed by Professor Detlef 
Schlondorff (Schlondorff 1996; Schlondorff and Banas 2009). 
 
Component of Mesangium Function 
Mesangial Cell 
• Production of Matrix. 
• Production of tissue inhibitor of metalloproteinases 
(TIMPs) and matrix metalloproteinases (MMPs) 
which control turnover of mesangial matrix. 
• Influence GFR by regulating blood flow through the 
glomerular capillaries or by altering capillary surface 
area.  
• Biological handling and clearance of 
macromolecules; advanced glycated end-products 
(AGE’s), immune complexes and lipids. 
• Exhibit phagocytic activity. 
• Production of vasoactive agents; angiotensin II (Ag 
II), nitric oxide (NO), prostaglandin E2 (PGE2) and 
inflammatory mediators. 
Mesangial Cell Matrix 
• Structural support. 
• May potentially trap LDL. 
• Has the capacity to oxidise LDL. 
• Interacts with mesangial cells and infiltrating cells 
via ligands. 
• Sequesters cytokines and growth factors. 
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1.2. GLOMERULAR MESANGIAL CELLS 
 
Mesangial cells are similar to vascular smooth muscle cells and are believed to 
have several functions in vivo. They contain large amounts of actin, myosin and 
tropomyosin indicative of a contractile function. The presence of receptors for the 
vasoactive peptide angiotensin II (AgII) support this role (Kreisberg 1983), which is 
important in the regulation of glomerular haemodynamics. When glomeruli are 
damaged, mesangial cells produce chemotactic factors such as monocyte chemotactic 
protein (MCP-1) (Cushing, Berliner et al. 1990), monocyte colony stimulating factor (m-
CSF) (Rajavashisth, Andalibi et al. 1990) and interleukin-1β (IL-1β) (Ku, Thomas et al. 
1992). Mesangial cells also secrete matrix, which creates the structural framework for 
the glomerular tuft as well as enzymes (and enzyme inhibitors) that maintain the balance 
between synthesis and degradation (Michael, Keane et al. 1980; Davies, Coles et al. 
1990; Sugiyama, Kashihara et al. 1998; Fogo 1999). Additionally the mesangial cell 
possesses phagocytic properties that contribute to the clearance and uptake of 
macromolecules from the glomerulus (Schreiner, Kiely et al. 1981; Davies 1994). Thus, 
inappropriate activation of mesangial cells may lead to excess matrix production, as well 
as release of chemotactic factors resulting in monocyte influx into the mesangium. 
Expansion of the mesangium, both due to the deposition of matrix proteins and 
an increase of mesangial cell numbers, is seen in kidney disease. Estimates of 
proliferation of mesangial cells in vivo suggest a low rate of about 1% per day (Pabst 
and Sterzel 1983; Davies 1994). Mesangial cell proliferation appears to play a role in the 
progression of glomerular pathology, particularly in the early stages. Matrix expansion is 
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generally preceded by mesangial cell proliferation in experimental models of 
glomerulonephritis. Persistent mesangial cell hyperplasia, caused by repeated injury, is 
believed to lead to irreversible scarring and eventual loss of glomerular function (Floege, 
Eng et al. 1993; Shimizu, Kawachi et al. 1999). The proliferation of mesangial cells is 
presumed to be a necessary physiological response required for the reconstitution of 
renal tissue.  
 
1.3. THE MESANGIAL CELL MATRIX 
 
The mesangial extracellular matrix fills the spaces between the mesangial cell 
and the perimesangial basement membrane, in addition a small amount of matrix may be 
found beneath the endothelium. In ultra-structural studies, this matrix has been 
characterized as a dense network of elastic microfibrils similar to the connective tissue 
of many other organs, and contains a network of intercellular channels that traffic 
macromolcules. In immunohistochemical studies, fibronectin is detected within the 
mesangium, along with laminin and type IV collagen, whilst type III collagen is found in 
the tubulointerstitium and type V collagen in the mesangial interstitium and the GBM 
(Oomura, Nakamura et al. 1989; Sugiyama, Kashihara et al. 1998). Fibronectin and 
Collagen type IV comprise the major protein components within the mesangial matrix, 
and were therefore the components studied in the experimental work described in this 
thesis. Minor components present in mesangial matrix include proteins such as laminin, 
vitronectin, entactin and proteoglycans. Fibronectin is the only component to be present 
exclusively within mesangial matrix and is specifically localized to areas immediately 
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surrounding mesangial cell processes. The other protein components mentioned are 
found distributed throughout the mesangial matrix, tubular basement membranes and 
Bowman's capsule (Madri, Roll et al. 1980). 
Fibronectin is closely associated with microfibrils, thus providing a link between 
mesangial cells and other matrix structures (Reale, Luciano et al. 1981; Brown, Andres 
et al. 1982; Cohen and Ku 1984). This microfibrillar network also appears to provide a 
solid base of contact between mesangial cells and the perimesangial GBM. Microfibrils 
are attached to sites in the mesangial cell membrane that serve to anchor intracellular 
actin filaments and penetrate the lamina densa to connect with the GBM. Not only does 
fibronectin serve to interconnect cells and matrix components, but also interconnects the 
microfibrils at their crossing points, so further stabilizing the entire matrix (Schwartz, 
Goldfischer et al. 1985). As a result of these interconnections, the microfibrillar network 
has sufficient three-dimensional tensile strength to balance distending forces acting in all 
directions. The importance of the mesangial matrix as a connecting structure between 
mesangial cells and the GBM is demonstrated by studies in which the failure of such 
connections produces miroaneurysms of the glomerular capillary tuft (Mosher 1984; 
Cohen, Saini et al. 1987; Proctor 1987; Yasuda, Kondo et al. 1996).  
Due to its nature, mesangial matrix has the potential to trap large molecules 
including lipoproteins such as LDL (Gupta, Rifici et al. 1992; Wheeler and Chana 
1993). The involvement of additional factors such as intra-renal hypertension, and 
inflammation are necessary for the induction and progression of lipid-induced renal 
dysfunction. Foam cells and lipid deposits are found in focal segmental sclerosis in 
human renal biopsies (Lee, Lee et al. 1991). Many of the features of progressive 
 29
glomerular and tubulo-interstitial diseases share biological mechanisms with those of 
atherosclerosis. 
This may be relevant in the pathogenesis of glomerular disease, particularly 
following an insult that has altered the glomerular filtration barrier permeability, 
allowing excess amounts of LDL to penetrate the mesangium. This process may 
potentially contribute to the formation of foam cells within the mesangium as explored 
later in the thesis. 
 
1.4. THE GLOMERULUS IN DISEASE 
 
 
Glomerular injury results from an initial pathogenic insult and may heal without 
consequences or lead to altered function of intrinsic glomerular cells and invasion of 
monocytes/macrophages from the circulation. Such changes result initially in mesangial 
cell proliferation, but if not resolved, continued cell proliferation leads to hyperplasia 
and the concomitant increase in matrix production to glomerulosclerosis. The term 
glomerulosclerosis is a non-specific finding on light microscopic examination that can 
be seen in any primary glomerular, tubulointerstitial, or vascular kidney disease.  
The process may initially involve only a small proportion of glomeruli (focal) 
and within these, only certain segments of the tuft (segmental). These localized lesions 
may progress to involve the whole glomerulus. The sclerotic areas consist of collapsed 
capillary loops obscured by an excess of mesangial matrix. 
A variety of early changes are recognized to precede glomerular obliteration. The 
basement membrane become thickened, is often detached from the overlying epithelial 
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cells and may be adherent to Bowman’s capsule. Epithelial cells are hypertrophied or 
absent at the sites of adhesions and electron microscopy reveals fusion of foot processes. 
Subendothelial eosinophilic deposits of hyaline material are found in both sclerotic and 
non-sclerotic areas of the glomerular tuft. Mesangial hypercellularity may result both 
from an increase in the number of contractile mesangial cells and from invasion of 
inflammatory macrophages. The mesangial area is also expanded by an excess 
deposition of mesangial cell matrix (Couchman, Beavan et al. 1994). 
Lipid deposition is seen within mesangial and epithelial cells both of sclerotic 
and non-sclerotic capillary loops but may also occur in interstitial regions (Chana, 
Wheeler et al. 2000). These histological changes correlate with the clinical 
manifestations of progressive glomerulosclerosis (Klahr, Schreiner et al. 1988; Magil 
and Frohlich 1991; Moorhead 1991). Proteinuria usually precedes a reduction in 
glomerular filtration rate and renal blood flow. Deterioration of renal function 
progresses and is frequently associated with the development of hypertension. Tubular 
atrophy leads to a reduction of the renal concentrating ability and impaired acid 
secretion.  
 
1.5. MESANGIAL CELL MATRIX IN GLOMERULAR DISEASE 
 
 
 The mesangial matrix is no longer seen as a static scaffold in which cells reside; 
but has been shown to be involved in cell proliferation, migration and cell-cell 
interactions. Turnover of the different extracellular matrix components is recognised as 
an active process with multiple levels of regulation (Sterzel, Schulze-Lohoff et al. 1992; 
 31
Yasuda, Kondo et al. 1996). Net deposition of matrix proteins, as seen in 
glomerulosclerosis, results from both quantitative and qualitative changes to mesangial 
matrix (Bruijn, Hogendoorn et al. 1988; Klahr, Schreiner et al. 1988; Olgemoller and 
Schleicher 1993; Harendza, Schneider et al. 1999). Changes in mesangial matrix may 
modify glomerular function by changing cell-cell interactions and by promoting 
infiltration and entrapment of macrophages.  
Matrix construction and remodelling involves three factors, matrix 
metalloproteinases (MMPs), plasmins that activate latent MMPs and tissue inhibitors of 
MMPs (TIMPs) (Raines 2000; Keeling and Herrera 2008). In inflammatory conditions, 
levels of growth factors such as TGF-β increase and can act to suppress the expression 
of matrix degrading plasminogen-activator inhibitor (PAI), and increase the activity of 
tissue inhibitors of metalloproteinases (TIMPs), thus favoring matrix accumulation. 
One consequence of mesangial matrix remodelling is that changes within this 
complex three-dimensional structure can reveal hidden sites previously unrecognizable 
to various adhesion receptors on the surface of cells coming into contact with the matrix. 
For example the RGD sequence of the fibronectin molecule is able to bind very late 
antigen (VLA)-5 present on the cell surface of monocytes (Pierschbacher and Ruoslahti 
1984; Hemler 1990). Also the CS-1 domain of fibronectin binds VLA-4 on monocytes 
by an RGD-independent mechanism (Wayner, Garcia-Pardo et al. 1989). Matrix 
remodelling, by exposing these sites, may promote monocyte adhesion to this matrix 
component.  
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1.6. THE MONOCYTE – MACROPHAGE LINEAGE 
 
Monocytes and macrophages comprise a family of phagocytic cells that are 
widely distributed throughout the body and are generally referred to as the mononuclear 
phagocyte system because of their common origin, similar morphology and common 
functions. Monocytes originate in the bone marrow, but become widely distributed in 
tissues where they mature into macrophages and take on specialist roles. Macrophages 
are well recognized for their ability to phagocytose, a property that enables them to 
eliminate pathogens and other foreign materials. However, these cells play a pivotal role 
in a variety of processes including inflammation, the induction and regulation of specific 
immune responses and tissue remodelling and repair. There are several basic properties 
of these cells that are relevant to their role in glomerular injury.  
Firstly, mononuclear phagocytes are highly mobile and have the capacity to 
adhere to various biological substrates, a function that facilitates their migration to sites 
of inflammation. Secondly, these cells secrete a range of soluble mediators that 
modulate functions of many other different types of cells. Thirdly, mononuclear 
phagocytes ingest and degrade various materials including senescent cells and tissue 
debris. Finally, mononuclear phagocytes can be activated by the external environment. 
Whilst mononuclear phagocytes play a critical role in host defense, these cells 
may also injure the host while exercising their defensive role. For example, monocytes 
have been shown to contribute to tissue damage by releasing proteolytic enzymes 
(Campbell, Silverman et al. 1989; Senior, Connolly et al. 1989), toxic oxygen 
metabolites (Carp and Janoff 1980; Campbell, Senior et al. 1982), pro-fibrotic cytokines 
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(Martinet, Rom et al. 1987; Shaw 1991) and other mediators (Tracey, Lowry et al. 
1986).  
Extravasation of monocytes from the vasculature into the mesangium involves 
directional migration of cells in response to chemoattractant factors. Since the 
mesangium forms the core of each tuft and is in direct contact with plasma constituents 
without an intervening membrane, monocytes directly encounter matrix during the 
migration stage. It is clear that regulated and reversible adherence of monocytes to 
extracellular matrix components is a prerequisite for the accumulation of these cells at 
sites of tissue inflammation (Snyderman and Goetzl 1981); however, little is known 
about the biological and pathological factors that regulate monocyte adherence to 
extracellular matrix and the resulting changes that occur to the monocyte.  
 
1.7. MONOCYTES 
 
Monocytes represent 3 to 8% of peripheral blood leukocytes. These mature cells 
measure 12 to 15 μM in diameter and posses a characteristic kidney-shaped nucleus. 
Their cytoplasm contains a well-developed Golgi apparatus, numerous lysosomal 
granules, microtubules and actin-containing filaments (which are cross-linked by actin-
binding protein and myosin). Monocytes are slowly motile, exhibit phagocytic activity 
and have a strong tendency to adhere and spread on glass surfaces (Lasser 1983). 
Monocytes give a positive reaction for non-specific esterases and contain peroxidase, 
acid phosphatase, lysozyme, aryl sulphatase and glucuronic acid (Yam, Li et al. 1971). 
Monocytes express HLA-DR antigens on their surface (McKinney, Boto et al. 1980; 
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Smith and Ault 1981) along with receptors for Fc component of IgG, complement C3 
(Huber, Polley et al. 1968; Schwartz, Bianco et al. 1975) and insulin (Schwartz, Bianco 
et al. 1975). 
 
1.8. MACROPHAGES 
 
Macrophages measure 20 to 80μM in diameter and contain a large vacuolated 
nucleus often with prominent nucleoli. Their cytoplasm contains a large well-developed 
Golgi apparatus, abundant rough endoplasmic reticulum and ribosomes, large 
mitochondria, microtubules, microfilaments and numerous lysosomes rich in hydrolytic 
enzymes.  
The transition from monocyte to macrophage is associated with increases in: 1) 
the number of lysosomes and mitochondria; 2) the activity of mitochondrial enzymes 
and the rate of cellular respiration; 3) phagocytic activity; 4) protein synthesis; 5) the 
capacity to interact with lymphocytes (Lasser 1983); 6) the expression of Scavenger 
receptor-A (Xu, Yu et al. 2006) and 7) the expression of Peroxisome proliferator-
activated receptor-gamma (PPAR-γ) (von Knethen and Brune 2003).  
Macrophages are also facultative anaerobes, with the exception of the pulmonary 
alveolar macrophage. They are highly motile and have marked phagocytic activity. In 
contrast to monocytes, macrophages have been shown to proliferate in response to 
certain stimuli in vitro (Diesselhoff-den Dulk, Crofton et al. 1979; Lasser 1983). As with 
monocytes, macrophages also express receptors for the Fc component of IgG, C3 
(Griffin, Spertini et al. 1990) and insulin (Bar, Kahn et al. 1977) however macrophages 
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also express receptors for IgE which is important in mediating host immunity to various 
parasites (Dessaint, Torpier et al. 1979; Melewicz and Spiegelberg 1980). Some 
macrophages express HLA-DR antigens and can function as antigen presenting cells for 
lymphocytes. The expression of HLA-DR antigen varies with the type of macrophage; 
only 15% of peritoneal macrophages express HLA-DR antigen compared with 50% of 
spleen and thymus macrophages (Cowing, Schwartz et al. 1978; Beller and Unanue 
1980). 
Macrophages are widely distributed throughout the body, but are particularly 
prominent in the spleen, lymph nodes, liver (Kupffer Cells), peritoneum, skin 
(Langerhans cells) and pulmonary alveoli. Macrophages resident in different tissues 
have widely differing morphological and functional properties. It has been postulated 
that the profile of local stimuli, to which macrophages are exposed in a particular tissue, 
influences their maturation and thereby accounts for their diversity of form and function 
(Cline, Lehrer et al. 1978).  
 
 
1.8.1. Macrophage Heterogeneity 
 
Local factors are important in determining the phenotype adopted by the 
recruited monocyte. The resultant tissue macrophages can be broadly divided into two 
groups; ‘resident macrophages’ and ‘inflammatory macrophages’(Gordon 2003).  
Tissue macrophages are heterogeneous and those isolated from different 
anatomical sites differ in function, presumably because of adaptive responses to the local 
microenvironment. Inflammatory macrophages are derived largely from circulating 
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monocytes which infiltrate damaged tissue; some also arise by local cell division. 
Different macrophage activation states have been recognized and result from exposure to 
specific stimuli that initiate differentiation into A) classically or B) alternatively 
activated macrophages (see table 1.2). 
Classically activated macrophages exhibit a Th1-like phenotype, promoting 
inflammation, extracellular matrix destruction, and apoptosis, while alternatively 
activated macrophages display a Th2-like phenotype, promoting extracellular matrix 
construction, cell proliferation, and angiogenesis (Erwig and Rees 1999; Duffield 2003). 
Although both phenotypes are important for clearance of pathogens and apoptotic cells, 
the classically activated macrophage tends to elicit chronic inflammation and tissue 
injury whereas the alternatively activated macrophage tends to resolve inflammation and 
facilitate wound healing. 
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Table 1.2. Stimuli for classically and alternatively activated macrophages. 
The table below summarises the various stimuli giving rise to a particular macrophage 
activation status as reviewed by Dr. Jeremy Duffield, a prominent author within the field 
inflammation research (Duffield 2003). 
 
Macrophage Activation Status Stimulus 
 
Classical Activation 
Pro-inflammatory cytokines 
Abnormal matrix 
Hypoxia 
Bacterial DNA 
 
Alternative Activation 
IL-4 
IL-10 
IL-13 
TGF-β 
 
As a result of their opposing phenotypic states, macrophages play a central role 
in innate protection both through the clearance of infective pathogens and through the 
repair of tissue injury that occurs, in part, as a consequence of this response. For 
example, the initial response of infiltrating monocytes to bacterial infection results in 
macrophage differentiation favoring a classically activated phenotype and so is cytotoxic 
and proinflammatory; then, once the infection is under control, macrophages 
phagocytose cellular debris and apoptotic bodies and begin tissue repair (Duffield 2003; 
Erwig, Kluth et al. 2003).  
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1.9. MONOCYTES/MACROPHAGES IN GLOMERULAR INJURY 
 
In the normal kidney there are small numbers of interstitial leukocytes thought to 
perform an immune surveillance function. These are predominantly monocytes. Only a 
small fraction of leukocytes in the normal kidney comprise B cells, T cells, natural killer 
cells, and neutrophils. 
In an acutely inflamed glomerulus, the predominant leukocyte is the macrophage. 
In human glomerular disease, macrophage numbers correlate with the extent of 
histological damage at the time of biopsy and predict renal outcome in certain disease 
settings (Ootaka, Saito et al. 1997). Macrophages expressing activation and proliferation 
markers have been identified in more aggressive forms of human and experimental 
glomerulonephritis and correlate with disease severity (Kerr, Nikolic-Paterson et al. 
1994; Lan, Nikolic-Paterson et al. 1995; Yang, Isbel et al. 1998). Strategies that limit 
disease progression in this setting include (A) the systemic depletion of macrophages; 
(B) Inhibition of pro-inflammatory cytokines that both activate and are produced by 
activated macrophages; and (C) the blocking of factors that promote the recruitment of 
macrophages to tissue sites (e.g; blockade of cytokines and adhesion molecules). 
   
1.9.1. The Potential For Monocyte-Matrix Interactions To Influence Glomerular 
Injury 
  
The mesangial matrix has the potential to play a key role in monocyte 
differentiation (Sugiyama, Kashihara et al. 1998; Jacob, Shastry et al. 2002). There are 
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two main mechanisms by which matrix can influence cell behavior. Firstly matrix 
harbours growth factors and growth factor binding proteins (Ignotz, Heino et al. 1989; 
Lee and Streuli 1999). These factors are passively sequestering but may be actively 
released by remodelling enzymes such as the MMPs and may thereby influence the 
behaviour of cells that are exposed to matrix components.  Secondly, matrix can directly 
regulate cells via receptor-mediated signalling (Schoecklmann, Rupprecht et al. 1996; 
Gauer, Yao et al. 1997; Hamerski and Santoro 1999). Since monocytes enter the 
mesangium through the fenestrated endothelium, they are unlikely to have undergone 
endothelial activation and therefore may encounter mesangial matrix in an inactivated 
state. The first activation signals that these cells encounter may therefore take the form 
of receptor-mediated signalling by matrix components. This monocyte-matrix 
interaction may play a key role in influencing monocyte behaviour within the 
glomerulus and the resulting macrophage phenotype is likely to be highly dependant on 
the local microenvironment within the glomerulus. For example, in a disease situation, 
matrix remodelling may be disrupted, leading to qualitative and quantitative changes in 
matrix composition which in turn may influence the sequestration of growth factors. A 
change in the composition of matrix components may potentially trigger different signal 
transduction cascades which, in turn, may influence monocyte behavior. (Wesley, Meng 
et al. 1998; Ingram, Ly et al. 1999; Urushihara, Takamatsu et al. 2010). Furthermore, 
subtle changes in the matrix composition resulting from enzymatic digestion may release 
bioactive matrix fragments or expose sequestered growth factors. 
As an example, fibronectin, one of the major matrix proteins, binds to very late 
antigen (VLA)-5 integrin subunits on the surface of monocytes. Binding of fibronectin 
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to this receptor depends on its conformation. Since fibronectin production is increased in 
diseased mesangial matrix, it is conceivable that an excess of this matrix component or 
conformational changes might influence these signalling pathways and thereby modulate 
monocyte activation and behaviour. The same may be true of collagen type IV, another 
matrix protein that is increased in diseased mesangial cell matrix. The RGD sequence of 
the fibronectin molecule binds VLA-5 present on the cell surface of monocytes thus 
signalling to the cell (Pierschbacher and Ruoslahti 1984; Hemler 1990). Likewise the 
CS-1 domain of fibronectin binds VLA-4 on monocytes by an RGD-independent 
mechanism (Wayner, Garcia-Pardo et al. 1989).  
 
1.10. LIPIDS IN GLOMERULAR INJURY 
 
The pathological effects of lipoprotein in progressive kidney disease may be 
similar to those in atherosclerosis. In recent years, an improved understanding of 
atherosclerosis has illuminated the pathology of glomerulosclerosis and supported the 
concept of lipoproteins as mediators of renal disease (Moorhead, Brunton et al. 1997). 
The possible role of lipoproteins in progressive renal disease may be understood in the 
more familiar context of atherosclerosis.  
Atherosclerosis results from a complex sequence of events in which normal 
cycling of LDL through the vascular endothelium is altered, leading to trapping of LDL. 
In addition, monocytes are recruited from the blood, smooth muscle cells proliferate and 
fibrous tissue is deposited. Trapped LDL may become oxidized, partly as a result of pro-
oxidant factors produced by monocytes (Parthasarathy, Printz et al. 1986; Quinn, 
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Parthasarathy et al. 1987; Boullier, Bird et al. 2001). The similarity between 
atherosclerosis and glomerulosclerosis is based on the assumption that the glomerulus 
posses cell types which are known to respond to lipoprotein injury, namely monocytes, 
or which resemble smooth muscle, namely the mesangial cell. Thus the mechanisms 
involved in atherosclerosis may also apply to glomerulosclerosis.  
Oxidised LDL (Ox-LDL) has been demonstrated to be more cytotoxic when 
compared with unmodified native LDL (Fernando, Varghese et al. 1993). Ox-LDL has 
also been proven to be important in lesion progression in atherosclerosis since uptake by 
macrophages via scavenger receptors causes the generation of foam cells. A similar 
mechanism may play an important role in lipid-mediated glomerulosclerosis. Ox-LDL 
has also been shown to stimulate monocyte influx (Pai, Kirschenbaum et al. 1995) by 
inducing mesangial cells to release chemotactic cytokines.  
Another prominent feature of lipid-induced glomerular injury is the accumulation 
of mesangial cell matrix. Studies in vitro indicate that lipid-activated mesangial cells 
produce excess matrix (Schlondorff 1993; Wheeler and Chana 1993; Lee 1999) as has 
been described in the atheromatous artery (Ross 1984). Lee et al has demonstrated that 
LDL stimulates mesangial cells through the induction of the phosphokinase C (PKC) 
pathway to synthesize TGF-β, which favours matrix production (Lee 1999). Chana et al 
reported that LDL also selectively enhances the synthesis of specific proteoglycans and 
hyaluronan in mesangial cells (Chana, Wheeler et al. 2000). The incubation of mesangial 
cells with native LDL (25-100 μg/ml) increased the synthesis and secretion of both 
fibronectin and laminin in a dose-dependant manner. Similarly, oxidized forms of LDL 
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(25-100 μg/ml) increased fibronectin and laminin and had a greater effect than native 
LDL (Roh, Kamanna et al. 1998).  
Therefore, lipoproteins and modified lipoproteins may get trapped in the 
mesangial matrix, become oxidized and get taken up by infiltrating 
monocyte/macrophages which form foam cells. 
 
1.11. MACROPHAGE DEACTIVATION AS A TARGET FOR THERAPY 
 
The exact mechanism of macrophage activation and accumulation within the glomerulus 
is largely unknown, although there is a considerable amount of experimental evidence 
implicating adhesion molecules as being relevant in the setting of glomerulosclerosis. 
Many of the interactions between adhesion molecules and infiltrating macrophages have 
been successfully blocked and could serve as targets for therapeutic interventions (Adler 
and Brady 1999; Allen, McHale et al. 1999; Chana and Wheeler 1999; Cook, Khan et al. 
2002). For example, the beta-1 integrin, α4β1, also known as very late antigen 4 (VLA-
4), is present on macrophages and binds to VCAM-1, which has been shown to be up-
regulated in the glomerular endothelium in experimental glomerulonephritis. Blocking 
using anti-α4 antibodies can prevent experimental crescentic glomerulonephritis as 
demonstrated by Allen et al (Allen, McHale et al. 1999) and has been shown to halt 
progression of established disease (Khan, Allen et al. 2003), making it a very attractive 
candidate for therapy. The humanized version of this anti-α4 monoclonal antibody 
known as Natalizumab has been used successfully in multicenter double-blind controlled 
studies in Crohn's disease and multiple sclerosis (Ghosh, Goldin et al. 2003; Miller, 
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Khan et al. 2003; Miller, Soon et al. 2007; Targan, Feagan et al. 2007). Despite its initial 
approval Natalizumab was withdrawn from the market by its manufacturer after it was 
linked with three cases of the rare neurological condition progressive multifocal 
leukoencephalopathy (PML) when administered in combination with interferon β-1a, 
another immunosuppressive drug often used in the treatment of multiple sclerosis (Tyler 
and Khalili 2005; Ransohoff 2007). After a review of safety information and no further 
deaths, the drug was returned to the US market in 2006 under a special prescription 
program. As of June 2009, ten cases of PML were known. However, twenty-four cases 
of PML had been reported since its reintroduction by October 2009, showing a sharp rise 
in the number of fatalities and prompting a review of the chemical for human use. By 
January 2010, 31 cases of PML were attributed to natalizumab, however it was not 
withdrawn from the market because its clinical benefits outweighed the risks involved 
(Ransohoff 2010; Steiner 2010). 
The beta-2 integrins include CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-
1/Complement receptor 3). A humanized monoclonal antibody to CD18 known as 
Efalizumab, which blocks CD11a/CD18 and CD11b/CD18 has been reported to reduce 
infiltrating leukocytes and improve vasculitic ulcers in four of five patients with 
systemic vasculitis (Lockwood, Elliott et al. 1999). Despite these beneficial effects 
Efalizumab was withdrawn from the market ten years later as it was associated in some 
cases with fatal brain infections (Major 2010). 
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1.12. AIMS OF THIS WORK 
 
Monocyte/macrophage accumulation within the glomerular mesangium is a 
recognized feature of glomerular injury in man. Although the mechanisms of 
macrophage trafficking and activation within the glomerulus are not properly 
understood, it is generally assumed that these cells are derived from circulating 
monocytes that migrate from the glomerular capillary lumen. During this process the 
monocyte encounters many extracellular signals that promote differentiation to a 
macrophage and other cellular responses. Recent studies suggest that such interactions 
may program macrophages, thereby potentially modifying their behavior in the setting 
of acute or chronic glomerular disease (Erwig, Kluth et al. 1998; Min, Lyons et al. 
2009).  
To begin to address the pathobiological importance of alterations in monocyte 
phenotype following interaction with matrix components, there is the need to firstly 
identify the nature of the interaction taking place and the resulting changes in monocyte 
phenotype. A representative matrix component (fibronectin) was used to conduct 
blocking studies to examine the extent to which binding to matrix modifies the secretory 
behavior of monocytes. 
Secondly to address the extent of monocyte differentiation into macrophages 
upon exposure to matrix, three macrophage specific markers were studied: a) the 
peroxisomal proliferator-activated receptor-γ (PPAR−γ), a nuclear receptor that acts as a 
transcriptional mediator for genes involved in lipid metabolism and adipogenesis 
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((Moore, Rosen et al. 2001), b) CD36, a class B scavenger receptor and c) Scavenger 
receptor class-A.  
Finally since LDL accumulation in the mesangium may contribute to glomerular 
injury, the interaction between this lipoprotein and the mesangial matrix was examined.  
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CHAPTER 2 
GENERAL METHODS 
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2.1. HUMAN MESANGIAL CELL CULTURE 
 
Techniques used for the isolation and maintenance of mesangial cells in vitro 
have been refined since these cells were first cultured in vitro in the late 1970’s. The two 
methods for mesangial cell culture used are enzymatic isolation (Striker and Striker 
1985) and explantation (Kreisberg and Karnovsky 1983; Striker, Lange et al. 1987). The 
starting material used for both methods is glomeruli isolated by differential sieving 
techniques. 
Enzymatic isolation uses collagenases to partially digest away the glomeruli, thus 
exposing the glomerular ‘cores’ comprising capillary loops and mesangium depleted of 
endothelial cells and the majority of epithelial cells. These cores are then explanted in to 
plastic cell culture flasks, and give rise to a heterogeneous outgrowth of cells within 2-4 
days.  
The choice of a culture medium with a high serum concentration (10-20%) 
promotes growth of mesangial cells rather than endothelial or glomerular epithelial cells, 
which require lower serum concentrations. The fact that mesangial cells attach more 
readily to plastic than endothelial and epithelial cells also aids in their purification. Thus 
within 2-3 passages, homogenous mesangial cell cultures are obtained. 
The alternative method of mesangial cell isolation (the explantation method), 
involves plating of undigested glomeruli into plastic flasks and use of high 
concentrations of foetal calf serum (FCS). Due to the different growth rates of intrinsic 
glomerular cell, the timing of subculture is used to select the cell type of interest. Both 
the enzymatic isolation and explantation methods provide reproducible and reliable 
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mesangial cell cultures, although cells have to be subcultured several times before 
sufficient numbers can be obtained for use in experiments. These cells retain many of 
the morphological and functional characteristics of mesangial cells in vivo (Lee 1995). 
 
2.1.1. Materials 
 
1) RPMI 1640 (Gibco BRL, Paisley, UK) 
2) Foetal calf serum (Gibco BRL, Paisley, UK) 
3) Glutamine (Sigma, Dorset, UK) 
4) Penicillin (Sigma, Dorset, UK) 
5) Streptomycin (Sigma, Dorset, UK) 
6) ITS (insulin-human transferrin-sodium selenite) (Sigma, Dorset, UK) 
7) Trypsin, ethylene diamine tetra acetic acid (EDTA) (0.025% and 0.01% respectively) 
8) 75 cm2 and 25 cm2 conical flasks (Falcon, UK) 
9) Sterile stainless steel sieves with the following mesh sizes: 425μm, 180μm and 
125μm. 
10) Glass syringe plunger (20ml) 
11) Collagenase (Type 1A) (Sigma, Dorset, UK) 
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2.1.2. Method for Human Mesangial Cell (HMC) culture 
 
 Human cadaver kidneys that could not be used for transplantation for technical 
reasons were used as a source of cultured cells with permission from the United 
Kingdom Transplant Sharing Scheme (UKTS). Under sterile conditions, the capsule was 
removed and the cortex excised from the underlying medulla. Cortical fragments were 
minced to a pulp and pushed through a 425μm mesh stainless steel sieve using a plastic 
syringe (20ml) plunger. The material on the underside of the sieve was washed through a 
180μm sieve and the glomeruli retained on the top surface of a third sieve with a mesh 
diameter of 125μm (Figure 2.1).  
 
Figure 2.1. Separation of Human Glomeruli by Differential Sieving 
 
 
 
These glomeruli were collected by aspiration, pelleted by centrifugation at 
1000g, placed in collagenase (type 1A) solution (400-600 units/ml) and digested for 20 
minutes at 37oC. The digestion was arrested by adding medium containing 20% FCS, the 
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glomeruli were harvested by centrifugation and plated on 25cm2 or 75cm2 Falcon tissue 
culture flasks depending upon the number of glomeruli obtained. 
 
2.1.3. Media and growth condition 
 
Growth medium consisted of 80% RPMI-1640 (Gibco BRL, Paisley, UK) and 
20% FCS (Life Technologies, Paisley, UK), supplemented with insulin (5μg/ml) human 
transferrin (5μg/ml), and sodium selenite (5ng/ml) (Insulin-Transferrin-Sodium selenite 
media supplement, Sigma). Benzyl penicillin (100 units/ml), and Streptomycin sulphate 
(50 μg/ml) were added to minimise the risks of infection. 
 
2.1.4. Passaging cells 
 
Primary cultures were left undisturbed for 9 days after which time the growth 
medium was changed. Glomeruli attached to the plastic within 3-4 days and after an 
initial outgrowth of epithelial cells (day 7-14), human mesangial cells began to 
predominate and outgrew the epithelial cells within 3 weeks of plating (Fernando, 
Varghese et al. 1993). Cells were subcultured when they reached confluence. Growth 
medium was removed and cells washed with PBS. Trypsin and ethylene diamine tetra 
acetic acid (EDTA), (0.025% and 0.01% respectively dissolved in sterile PBS, Life 
Technologies) was then added and the cells incubated for 3-5 minutes at 37oC. Cell 
detachment was assessed by phase-contrast microscopy and enhanced by vigorous 
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agitation. The enzymatic action of trypsin was arrested by adding growth medium; next 
the detached cells were pelleted by centrifugation at 1000g for 10 minutes. The cell 
pellet was then re-suspended in fresh growth medium. The cells detached from one 
25cm2 flask were placed in two new flasks of the same size at a plating density of 1-5 x 
106 cells/ml. Medium was changed every 3-4 days and subsequent passages carried out 
at 7-14 day intervals when confluence was reached. Mesangial cells from passages 2-10 
were used in characterisation studies and for the experiments described in the following 
chapters.  
 
2.2. MESANGIAL CELL MATRIX ISOLATION 
 
Mesangial cells were grown to approximately 90% confluence, washed 3 times 
with RPMI medium then growth arrested in serum-free RPMI medium for 48 hours. The 
cell layer was removed by addition of 2.5 mM NH4OH and 0.1% Triton X-100 for 3 
minutes, leaving behind cell matrix (Weiss and Regiani 1984). This matrix layer was 
then washed 3 times with PBS before commencing adhesion experiments. 
For experiments requiring solubilised matrix, the isolated matrix layer described 
above was collected by mechanical scraping and sonicated for 30 seconds using an 
ultrasonic probe to apply ultrasound energy.  
Protein concentration of matrix was carried out using a modified Lowry method 
(Lowry OH 1951), the matrix was then re-suspended in RPMI medium at concentrations 
of 10, 50, 100 and 500 μg/ml. Matrix was isolated from mesangial cells derived from 4 
different glomerular preparations and used on the day of isolation. The matrix contained 
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very low concentrations of TGF-β (<0.05 pg/μg), and virtually undetectable amounts of 
TNF-α (<0.02 pg/μg), IL-1β (<0.003 pg/μg) and IL-6 (<0.003 pg/μg) as measured by 
enzyme-linked immunosorbent assay (Felisaz, Boumediene et al.) (R&D Systems, 
Abingdon, Oxon, UK) according to the manufacturer’s instructions. Individual matrix 
proteins; collagen type IV, fibronectin and laminin were sourced from Sigma (Sigma 
Chemical Co, Poole, Dorset, UK). All reagents and materials including matrix and 
buffers were tested for endotoxin contamination using a Limulus amebocyte lysate test 
kit (Sigma) and proved negative  
 
2.3. IMMUNOHISTOCHEMICAL LABELLING 
 
These studies were designed to confirm that matrix preparations were free of mesangial 
cells and contained fibronectin. Human mesangial cells were grown on glass cover slips, 
then removed from the underlying matrix as described in section 2.2. The remaining 
matrix was then fixed with 100% ethanol and exposed to a mouse monoclonal anti-
human fibronectin antibody for 30 minutes at room temperature. Cells and matrix were 
then exposed to a bridging rabbit anti-mouse antibody for one hour, followed by an 
alkaline phosphatase-conjugated mouse anti-alkaline phosphatase complex. After 
rinsing, the coverslips were developed using fast red for 5 mins and counter-stained for 
nuclei with Mayer’s acid alum haematoxylin. 
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2.4. FIBRONECTIN ASSAY 
 
The synthesis of fibronectin by mesangial cells was measured by ELISA 
(Burton, Combe et al. 1996). After washing, the cell layer was solubilized overnight in 
wash buffer (0.3M NaCl, 0.1% Triton X-100 in PBS) containing 1% P40.  
The standards and appropriately diluted cell layer extracts were then incubated 
overnight in wells that had been pre-coated with a rabbit polyclonal anti-human 
fibronectin antibody (1:1000, Sigma). This was followed by the addition of a mouse 
monoclonal anti-human fibronectin (1:500, Sigma) and a horseradish peroxidase-
conjugated anti-mouse antibody (1:1000, Dako) for 2 hours each.  
Plates were then developed using a phenylenediamine substrate. After the color 
had appeared, the reaction was stopped by adding 1M sulphuric acid and the absorbance 
recorded at 492 nm. All fibronectin concentrations were measured as ng/ml and then 
expressed as % of control (growth arrested cells). 
 
2.5. CULTURE OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS 
 
2.5.1. Materials 
1) RPMI 1640 with L-glutamine containing 25mm HEPES 
2) 10% FCS (fibronectin free) 
3) 1% L-glutamine (200mM) 
4) 1% Penicillin-streptomycin solution (10,000 units and 10,000 μg/ml respectively) 
5) Ficoll-Hypaque (Pharmacia Biotech AB, Uppsala, Sweden 
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6) 0.15 mmol/L sterile NaCl solution 
7) 5 mmol/L sterile EDTA 
 
2.5.2. Methods of peripheral human blood mononuclear cell culture 
 
Peripheral blood was collected into lithium-heparin tubes and diluted with an 
equal volume of sterile 0.15 mol/L NaCl solution. The diluted blood (30ml) was layered 
over ficoll-Hypaque (Pharmacia Biotech AB, Uppsala, Sweden) (15ml) and centrifuged 
at 900 g for 30 min at room temperature. The mononuclear cells were harvested and 
washed twice with 20 ml of sterile 0.15 mol/L NaCl solution. The cells were re-
suspended at 2 x 106 cells/ml in supplemented RPMI 1640 medium, containing 10% 
fibronectin free foetal calf serum, L-glutamine and penicillin-streptomycin. An adherent 
step was then performed to separate the monocytes, which are the adherent cells, from 
the lymphocytes which are the non-adherent cells (Ackerman and Douglas 1978). This 
involved plating aliquots (1 ml) of the mononuclear suspension into 35 x 10 mm tissue 
culture dishes. The dishes were incubated at 37oC for 2 hours in a humidified incubator 
at 37oC, 5% CO2. Non-adherent cells were removed by washing four times with 2 ml of 
sterile 0.15 mol/L NaCl solution. The adherent cells were then detached by incubating 
the dishes with sterile 0.15 mol/L NaCl solution containing 5 mmol/L EDTA for 45 min 
at 4oC whilst gently agitating. The dishes were again washed three times with 2 ml 
sterile 0.15 mol/L NaCl solution. The suspension of previously adherent cells was 
centrifuged (600 g for 5 min at 4oC) and the supernatant was discarded.  
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The cells were re-suspended in 2 ml of RPMI medium, counted three times using 
a haemocytometer and the mean value was determined. Cell viability was shown to be 
between 90 and 95% when assessed by cellular exclusion of trypan blue under phase-
contrast microscopy.  
For experiments the cells were re-suspended at 1.5 x 106 cells/ml in 
supplemented RPMI medium with 5% fibronectin-free homologous serum. All reagents 
and materials used in the experiment had been tested for endotoxin contamination using 
a Limulus amebocyte lysate test kit (Sigma) and proved negative. 
 
2.6. CULTURE OF THE HUMAN MONOCYTE CELL LINE THP-1 
 
The THP-1 cell line was originally derived from the peripheral blood of a one 
year old male with acute monocytic leukaemia (Tsuchiya, Yamabe et al. 1980). These 
cells were sourced from ATCC (Middlesex, UK). The cells are grown in continuous 
suspension in the medium described below and can be differentiated into macrophages 
by exposure to phorbol esters (Tsuchiya, Yamabe et al. 1980; Tsuchiya, Kobayashi et al. 
1982). 
 
2.6.1. Materials 
 
Medium A 
1) RPMI 1640 with L-glutamine containing 25mm HEPES 
2) 10% FCS 
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3) 1% L-glutamine (200mM) 
4) 1% Penicillin-streptomycin solution (10,000 units and 10,000 μg/ml respectively) 
5) 40 nmol/ml mercaptoethanol 
 
Medium B 
1) RPMI 1640 with L-glutamine containing 25mm HEPES 
2) 10% FCS  
3) 1% L-glutamine (200mM) 
4) 1% Penicillin-streptomycin solution (10,000 units and 10,000 μg/ml respectively) 
5) 40 nmol/ml mercaptoethanol 
6) 125 nmol/ml phorbol ester myristate acetate (Chinetti, Griglio et al.) 
 
2.6.2. Method of human monocyte THP-1 cell culture 
 
Cells were grown to a concentration of 2-4 x 106 cells/ml during a 7 day growth 
period and were then harvested by centrifugation for 10 min at 400 g and re-suspended 
in medium A to give a concentration of 1 x 106 cell/ml. 
To differentiate THP-1 monocytes into macrophages, cells were re-suspending in 
medium B at a concentration of 5.25 x 105 cells/ml and 1 ml of this suspension placed 
into each well of a 12-well plate. The medium was then replaced with 1ml/well of 
medium B every 2 days and the plates incubated in a humidified incubator at 37oC, 5% 
CO2 for 5 days. For experiments the cells were re-suspended at 1.5 x 106 cells/ml in 
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supplemented RPMI medium with 5% fibronectin-free homologous serum. All reagents 
and materials used in the experiments including matrix and buffers had been tested for 
endotoxin contamination using a Limulus amebocyte lysate test kit (Sigma) and proved 
negative. 
 
2.7. CULTURE OF THE HUMAN MONOCYTE CELL LINE U937 
 
Human myelomonocytic leukaemia cells of the U-937 cell line (European 
Collection of Cell Culture, Salisbury, UK) were grown in supplemented RPMI 1640 
medium as above. Cultures were expanded by seeding approximately 2 x 106 cells into 
15 ml 20% foetal calf serum supplemented RPMI medium in T75 culture flasks (Falcon 
Scientific supplies, London, UK) and medium changed every 4 days. For experiments, 
cells were centrifuged at 180g for five minutes. The monocyte pellet was rinsed twice in 
RPMI medium. For experiments the cells were re-suspended at 1.5 x 106 cells/ml in 
supplemented RPMI medium with 5% fibronectin-free homologous serum. All reagents 
and materials used in the experiments including matrix and buffers had been tested for 
endotoxin contamination using a Limulus amebocyte lysate test kit (Sigma) and proved 
negative. 
 
2.8. FLOW CYTOMETRY ANALYSIS OF MONOCYTES 
 
Monocyte associated cell surface markers, CD 69 and late HLA-DR expression 
were assessed on peripheral blood and U-937 monocytes. A change in the expression of 
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these antigens would allow us to identify if the monocytes have become activated. 
Briefly, 200μl of monocyte cell suspension (1.0 x 106 cells/ml) was aliquoted and 
centrifuged at 400g for 5 minutes. The pellet was resuspended in 80μl of PBS/10% 
FCS/0.1% sodium azide. Then 10μl of anti-CD 14 antibody coupled to fluorescein 
isothiocyanate (FITC) (Becton Dickinson, Cowley, UK) together with 10μl of either 
anti-CD 69 antibody coupled to phycoerythrin (PE) (Becton Dickinson, Cowley, UK) or 
anti-HLA-DR PE antibody (Becton Dickinson, Cowley, UK) was added and samples 
incubated in the dark at room temperature for 30 minutes. Cells were then washed with 
PBS containing 1% BSA and fixed for flow cytometric analysis in equal amounts of 
PBS/10% FCS/0.1% NaN3 and 2% paraformaldehyde solution. Data were acquired on a 
FACS 440-flow cytometer using an argon ion laser at 488nm. FITC fluorescence was 
assessed using a 530 + 15 nm filter and PE using a 575 + 15nm filter. Collected data 
were edited and analysed using in house software. 
 
2.9. SCANNING ELECTRON MICROSCOPY 
 
 I thank Professor Alan Phillips at the Department of Paediatric Gastroenterology, 
Royal Free Hospital for the initial training and subsequent use of his departmental 
scanning electron microscope. Coverslips measuring 1cm in diameter were placed at the 
bottom of 24 well plates. Mesangial cells were grown to confluence within the wells and 
relevant wells were subsequently treated with Trypsin and ethylene diamine tetra acetic 
acid (EDTA), (0.025% and 0.01% respectively dissolved in sterile PBS, Life 
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Technologies) to expose the underlying matrix and incubated with human PBMCs for 48 
hours in a humidified incubator at 37oC, 5% CO2.  
After the culture period, tissue specimens were washed three times with fresh 
culture medium to remove any non adherent cells, fixed in 3% phosphate-buffered 
glutaraldehyde, and post fixed in 1% aqueous osmium tetroxide. For scanning electron 
microscopy (SEM), specimens were taken through a graduated series of ethanol and 
critical point dried in liquid CO2, using a Polaron E3000 critical point drying apparatus. 
Samples were then sputter coated with gold-palladium in a Polaron E5100 series II 
coating system and examined in a JOEL JSM-5300 scanning electron microscope. Scans 
of 5 random fields of view for each specimen were taken. 
 
 
 
2.10. MONOCYTE ADHESION ASSAY 
 
The binding of U-937 and peripheral blood-derived monocytes to mesangial 
matrix was determined using a colorimetric method as described by Mené et al (Mene, 
Fais et al. 1995). Mesangial cells plated at a density of 25,000 cells/well in 24 well 
plates were grown for 96 hours then growth arrested for 48 hours in serum free medium. 
To determine the impact of matrix accumulation, mesangial cells were prestimulated 
with TGF-β (10 ng/ml), TNFα (10 ng/ml) or a combination of both cytokines for 48 
hours. After thorough washing, the cell layer was removed by adding 2.5 mM NH4OH 
and 0.1% Triton X-100 for 10 minutes as described by Weiss and Regiani leaving 
behind the cell matrix which was also washed extensively (Weiss and Regiani 1984). 
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Monocytes (2 x 106 cells/well) were then incubated with the residual matrix produced by 
the pre-stimulated or non-stimulated mesangial cells for one hour at 37oC in serum free 
medium. Non-adhered monocytes were removed by washing. Adhered cells were fixed 
with 1.0% glutaraldehyde and stained with a crystal violet solution (0.1% (w/v). Cells 
were washed, solubilized overnight in Triton X-100 (1.0%) and absorbance readings 
recorded at 595nm. The results obtained were corrected by subtracting background 
staining of the underlying matrix. The corrected values were then taken to be 
proportional to the number of monocytes bound to matrix.  
To confirm the role of fibronectin and specific monocyte integrins in the binding 
process, anti-human fibronectin (25 μg/ml, Sigma), anti-VLA-4 (10 μg/ml, AMS 
Biotechnology) and anti-VLA-5 (5 μg/ml, AMS Biotechnology) antibodies were used in 
blocking experiments. In each case, the optimal antibody concentrations were chosen on 
the basis of preliminary experiments using a range of dilutions. The anti-human 
fibronectin antibody was pre-incubated with matrix whilst either U937 or peripheral 
blood-derived monocytes were pre-exposed to the anti-integrin antibodies for one hour 
at room temperature prior to the adhesion assays. 
 
2.11. CYTOKINE PRODUCTION 
 
IL-1β, IL-6 and TNFα secreted by peripheral blood-derived monocytes 
following exposure to matrix and individual protein components were measured by 
ELISA (R&D Systems). Briefly monocytes (0.5 x 106 cells/ml) were added to 24 
multiwell plates containing mesangial matrix or to empty plastic wells for 24 hours. 
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Alternatively, solubilized matrix, fibronectin, laminin and collagen IV were added to 
monocytes pre-plated in 24 well plates. For positive and negative controls, monocytes 
were incubated in plastic wells for 24 hours with or without lipopolysaccharide (LPS, 10 
μg/ml) respectively. In each case, the resulting conditioned medium was collected and 
spun at 6500 rpm for 5 mins on a microfuge to remove non-adherent monocytes. 
Samples were stored at -80oC prior to the analysis. All reagents and materials used in the 
experiments including matrix, matrix components and buffers were tested for endotoxin 
contamination using a Limulus amebocyte lysate test kit (Sigma) and proved negative. 
 
2.12. THYMIDINE INCORPORATION 
 
 The ability of mesangial cell matrix to induce proliferation of blood-derived and 
U-937 monocytes was assayed by measuring the incorporation of 3H-thymidine. Briefly, 
3H-thymidine (3.6 Ci/ml) was added to peripheral-blood derived (0.25 x 106 cells/ml) or 
U-937 monocytes (1.25 x 106 cells/ml) plated on matrix or in empty plastic culture 
plates for up to 96 hours. At the end of the incubation period, the adherent and non-
adherent cells were collected, washed with PBS and treated with 50% methanol 
containing 10% glacial acetic followed by 10% Trichloroacetic acid. After further 
washes, the cells were solubilized in 0.1 M NaOH containing 1% SDS and the 
radioactivity incorporated determined by liquid scintillation counting. 
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2.13. GELATINOLYTIC ACTIVITY 
 
The secretion of gelatinolytic enzymes by peripheral blood-derived monocytes 
incubated with mesangial cell matrix and matrix proteins was determined by 
zymography as previously described (Martin, Davies et al. 1989). Briefly, mesangial 
cells grown in 24 well plates were removed from the underlying matrix and incubated 
with human monocytes (0.5 x 106 cells/ml) for 24 hours in the absence of foetal calf 
serum. The resulting conditioned medium was isolated, centrifuged and stored at –80oC 
for batch analysis.  
The enzyme activity of MMP-9 was assessed by SDS-PAGE using a 7.5% gel, 
incorporating gelatin (1 mg/ml), under non-reducing conditions. Following 
electrophoresis the gel was washed with 2.5% Triton X-100 for 1 hour and incubated in 
50 mM Tris HCl pH 7.6 containing CaCl2 (10 mM) and Brij (0.05%) at 37oC overnight. 
The gel was then fixed and stained with Coomassie blue and enzymatic activity 
demonstrated by zones of lysis, analysed by comparison to controls and quantified by 
densitometry. 
 
2.14. ANALYSIS OF TIMP I AND TIMP II 
 
Concentrations of TIMP I and TIMP II secreted by blood-derived monocytes into 
conditioned medium were measured by ELISA (Baker, Tickle et al. 1994; Martin, 
Steadman et al. 1998). Standards of TIMP 1 (0.15 to 150 ng/ml) and TIMP II (0.15 to 
300 ng/ml) were prepared using purified TIMP kindly supplied by Prof. T. E. Cawston 
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(Department of Medicine, University of Newcastle, UK). Antibodies to TIMP were 
kindly provided by Dr. A Docherty, Cell Tech, Slough, and Dr G Murphy, University of 
East Anglia, Norwich, U.K. 
 
2.15. RNA ISOLATION 
 
Total RNA was isolated from cultured human mesangial cells by the 
guanidinium method (Chirgwin, Przbyla et al. 1979). In this method, Guanidine 
thiocyanate, in association with β-mecaptoethanol and N-lauroyl sarcosine powerfully 
inhibit RNase and act to disrupt the nucleoprotein complex, allowing RNA to be 
released into solution. Intact RNA was purified from contaminants by 
phenol:chloroform extraction. RNA selectively partitions into the aqueous phase, free 
from DNA and protein and was concentrated by precipitation with isopropanol (Perry, 
La Torre et al. 1972; Chirgwin, Przbyla et al. 1979). 
 
2.15.1. Materials 
 
1) RNase-Free Water: ddH2O was treated with 0.1% DEPC (Sigma, Dorset, UK) at 37oC 
overnight, then autoclaved. 
2) 0.75M sodium citrate (pH 7.0): 11.029g of citrate 3 Na (Sigma, Dorset, UK) was 
dissolved in dH2O and reconstituted to 50ml. Next 0.1ml of DEPC was added and the 
mixture stirred for 2 hours, then autoclaved. 
 64
3) 10% Sarcosyl: 10g of n-lauroylsarosine sodium salt (Sigma, Dorset, UK) was 
dissolved in dH2O and reconstituted to 100ml. Then 0.2ml of DEPC was added and the 
mixture was stirred for about 2 hours, then autoclaved. 
4) Denaturing solution: 250g of guanidinium thiocyanate (GTC) (Sigma, Dorset, UK) 
(final concentration 4M) was mixed with 17.6ml of 0.75M sodium citrate (pH 7.0) (final 
concentration 25mmol/l), 26.4ml of 10% sarcosyl (final concentration 0.5%) and 293ml 
of RNase-free water. The mixture was stirred at 65oC until GTC was dissolved. Before 
use, 2-mercaptoethanol was added (Sigma, Dorset, UK) 0.36ml per 5ml solution. 
5) 2M Sodium acetate (pH 4.0): 27.216g sodium acetate (Sigma, Dorset, UK) was 
dissolved in dH2O. The pH was adjusted using glacial acetic acid, reconstituted to 
100ml, then filtered. 
6) 0.5M EDTA: 186.1g of disodium ethylene diamine tetraacetate (Sigma, Dorset, UK) 
was added to 800ml of dH2O and stirred vigorously. The pH was adjusted to 8.0 with 
NaOH. The solution was dispensed into aliquots and sterilised by autoclaving. 
7) 3M Sodium acetate (pH 5.2): 408.1g of sodium acetate was dissolved in dH2O and pH 
adjusted to 5.2 with glacial acetic acid. The volume was adjusted to 1 litre. The solution 
was dispensed into aliquots and sterilised by autoclaving. 
8) Phenol: Chloroform:Isoamyl Alcohol (125:24.1, pH 4.7) (Sigma, Dorset, UK) 
9) Isopropanol (Sigma, Dorset, UK) 
10) Ice-cold 75% ethanol, RNase-free (Sigma, Dorset, UK) 
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2.15.2. Steps to avoid Ribonuclease contamination 
 
Sterile disposable plastic ware was used for handling RNA. Non-disposable 
glassware and plastic ware were treated before use to ensure that they were RNase-free. 
Glassware was baked at 200oC overnight. Plastic ware was thoroughly rinsed with 0.1N 
NaOH, 1mM EDTA and then with nuclease-free water. RNase-free materials were used 
for weighing chemicals. Solutions were treated by the addition of diethyl pyrocarbonate 
(DEPC) 0.1% overnight at room temperature, and then autoclaved for 30 minutes to 
remove any traces of DEPC. Tris buffers were prepared using containers which were 
designated for Tris only and which had been treated with DEPC and autoclaved. 
 
 
 
2.15.3. Total RNA purification 
 
Human mesangial cells were cultured in 75 cm2 flasks. Before RNA extraction, 
cells were pelleted and washed once in ice-cold phosphate-buffered saline and lysed in 
ice-cold denature solution using 600μl per 1 flask (about 5x106). Cell lysates were 
sheared eight times through a 21-gauge needle. Next, 60μl of 2M sodium acetate (pH 
4.0) was added to the lysate in each flask and mixed thoroughly by inverting 4-5 times. 
One volume of phenol:chloroform:isoamyl alcohol was then added. The mixture was 
vortexed after each addition and for at least 10 seconds after the final step. The emulsion 
was incubated on ice for 15 minutes and then centrifuged at 12,000 rpm for 20 minutes 
at 4oC. The aqueous phase was carefully transferred to a fresh RNase free tube, taking 
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care not to touch the interface. To this an equal volume of isopropanol was added and 
mixed, then precipitated by incubating at –20oC for 2 hours. The crude RNA pellet was 
recovered by centrifugation at 12,000 rpm for 20 minutes at 4oC and washed by 
resuspension in 1ml of 75% ice-cold ethanol.  
The RNA was recovered by centrifugation at 12,000 rpm for 10 minutes at 4oC. 
The pellet was then dried in air and resuspended in 150μl RNase free water. 10μl of 3M 
sodium acetate (pH 5.2) was added and mixed thoroughly by inverting the tube 4-5 
times. One volume (150μl) of phenol:chloroform:isoamylalcohol was added. The 
mixture was then vortexed for 10 seconds, then centrifuged for 10 minutes at 4oC. The 
aqueous phase was carefully transferred to a fresh RNase free tube, then an equal 
volume of ethanol (100%) was added, this was then mixed and precipitated by 
incubating at –20oC for 2 hours. The concentration of RNA was determined by 
measuring the absorbance at 260nm using a spectrophotometer. 
 
2.16. RT-PCR 
 
The RNA sample was reverse transcribed to cDNA to provide the necessary 
DNA template for the thermostable polymerase. (Becker-Andre and Hahlbrock 1989). 
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2.16.1. Materials 
 
All reagents were obtained from Perkin-Elmer (PE Applied Biosystems Ltd, 
Warrington, Cheshire, UK) 
1) 10x PCR buffer II: 500mmol/l KCl, 100mmol/l Tris/HCl 
2) 25 mmol/l MgCl2 solution 
3) dNTPs: 10mmol/l deaoxyribonucleoside triphosphates 
4) Random hexamers 50μmol/l 
5) RNase inhibitor (20 Unit/l) 
6) M-MLV reverse transcriptase (50 Unit/l) 
7) Taq DNA polymerase (5 Unit/l) 
 
 
 
 
2.16.2. Method of RT-PCR 
 
Total RNA (500ng) was used as a template for RT-PCR. The RT reaction was set 
up in a 20μl mixture containing 50mmol/l KCl, 10mmol/l Tris/HCl, 5mmol/l MgCl2, 1 
mmol/l of each of the dNTPs, 2.5μmol/l random hexamers, 20 U RNase inhibitor 
(RNAsin), and 50 U of M-MLV reverse transcriptase. Incubations were performed in a 
DNA Thermal Cycler (Perkin-Elmer 9600) for 10 minutes at room temperature, 
followed by 30 minutes at 42oC and 5 minutes at 99oC. After cDNA synthesis by RT, 
the incubation mixture was split into two 10μl aliquots for separate amplification of 
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cDNA using specific primers. For PCR, the final concentrations of the PCR reaction 
mixture were 50mmol/l KCL, 10mmol/l Tris/HCl, 2mmol/l MgCl2, 200μmol/l dNTPs, 
0.125-0.25μmol/l of primers, 1.25U Taq DNA polymerase. After incubation at 145 
seconds at 95oC, 30 seconds at 55-65oC and 60 seconds at 72oC twenty microlitres of 
each PCR reaction were subjected to electrophoresis in a 2% agarose gel. 
 
2.17. ANALYSIS OF PPAR-γ, CD36 AND SCAVENGER RECEPTOR-A GENE EXPRESSION 
USING RT-PCR 
 
Based on previous experiments, monocytes were incubated in the presence of 
soluble matrix for various times up to 120 hours (5 days) at 37oC in a humidified 
atmosphere of 5% CO2. PMA (125 nM) and cell culture grade bovine serum albumin 
(BSA, 500 μg/mL) (Sigma) served as positive and negative controls respectively. Cells 
were trypsinised and recovered by centrifugation. Total RNA (approximately 500 ng) 
was extracted from the cell pellet by a SDS/double phenol extraction method (Ruan, 
Varghese et al. 1999). The RNA was used as a template for reverse transcriptase-
polymerase chain reaction (RT-PCR) and the resultant cDNA was amplified for PPAR-
γ, CD36 and scavenger receptor-A by PCR, using β-actin as a control. The following 
primers were used: PPAR-γ upper primer 5’-GGC AAT TGA ATG TCG TGT CTG 
TGG AGA TAA 3’ and PPAR-γ lower primer 5’-AGC TCC AGG GCT TGT AGC AGG 
TTG TCT TGA-3’, CD36 upper primer 5’ CAG CCT CAT TTC CAC CTT TTG TT and 
CD36 lower primer 5’ GTT GAC CTG CAG CCG TTT TG, scavenger receptor-A 
upper primer 5' TCG CTC AAT GAC AGC TTT GC 3’ and scavenger receptor-A lower 
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primer 5’ CCA TGT TGC TCA TGT GTT CC 3’, β-actin upper primer 5'-ATG GAT 
GAT GAT ATC GCC GCG-3’ and β-actin lower primer 5’-CTA GAA GCA TTT GCG 
GTG GAC GAT GGA GGG GCC-3’ (Biogenesis, Poole, UK). Twenty microlitres of 
the PCR product was subjected to electrophoresis on a 2% agarose gel and bands 
visualised by staining with ethidium bromide under UV light. Gels were subjected to 
densitometric analysis using a Gel Doc 2000 scanner (Bio-Rad, Herts, UK), and band 
intensity normalised to β-actin to control for variations in loading then normalised to the 
appropriate control conditions (100%).  
 
2.18. Analysis Of PPAR-γ Protein Expression Using Western Blot 
Modulation of PPAR-γ in THP-1 monocytes in response to mesangial cell matrix 
was examined by Dr. Ravinder Chana using Western blot analysis. Monocytes seeded 
into 24 well plates at a density of 1.5 x 106 cells/well and incubated with matrix (500 
μg/ml) for various times up to 48 hours. Supplemented RPMI media containing either 
PMA or BSA served as a positive and negative control respectively. After stimulation, 
cells were collected, washed twice with cold PBS and lysed in Laemmli buffer (60 
mmol/L Tris, pH 6.8, 10% glycerol, 2% sodium deoxycholate, 100 mmol/L 
dithiothreitol and 0.01% bromophenol blue). Cell lysates were heated at 100oC for 5 
minutes and subjected to 10% SDS-polyacrylamide gel electrophoresis (Bio-Rad, Herts, 
UK). Proteins were transferred on to Protran nitrocellulose membranes (Schleicher and 
Schuell BioSciences GmbH, Dassel, Germany). PPAR-γ was detected using a 
monoclonal antibody (SC7273; SantaCruz Biotech, Cambridge, UK) at 1:1000 dilution 
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and a secondary horseradish peroxidase-linked anti-mouse IgG antibody (A4416; 
Sigma) at 1:2000. Bound antibodies were visualized using an enhanced 
chemiluminescence system (Amersham Biosciences, Bucks, UK). For densitometric 
analysis, bands from Western blots were scanned and quantified using Scion Image 
version 4.0.2. 
 
2.19. MODIFIED LOWRY ASSAY FOR LIPOPROTEIN AND CELL MEMBRANE PROTEIN 
ESTIMATION 
 
Protein concentration was estimated using a modified Lowry assay as described 
by Markwell. (Markwell, Haas et al. 1978). 
 
2.19.1. Materials  
 
1) 100μg/ml stock solution of BSA (Sigma Ltd. Dorset UK) 
2) Reagent A: consisting of 2% Na2CO3, 0.4% NaOH, 0.16% Sodium tartrate and 1% 
SDS (Sigma Ltd. Dorset UK) 
3) Reagent B containing 4% CuSO45H2O (Sigma Ltd. Dorset UK) 
4) 1 N Folin-Ciocalteu solution (F-C) (Sigma Ltd. Dorset UK) 
 
 
 
 
 
 71
2.19.2. Lowry Assay 
 
BSA stock was diluted in dH2O to obtain standards as follows: 0, 5, 10, 20, 40, 
60, 80 and 100μg/ml. Next 3ml of reagent C (solution A: solution B at 100:1) were 
added to 1 ml of sample containing 10-100μg of protein and incubated at room temp for 
10 min. Next 0.3 ml of 1 N F-C reagent was added and vortex mixed then incubated for 
45 min at room temperature. Finally, absorbance was read at 660nm using a 
spectrophotometer and the content of sample protein calculated using the BSA standard 
curve. 
 
2.20. PREPARATION OF HUMAN LOW DENSITY LIPOPROTEIN (LDL)  
 
LDL was isolated from plasma by sequential ultracentrifugation as described by 
Havel (Havel, Eder et al. 1955). 
 
2.20.1. Materials 
 
1) 0.2M disodium EDTA (pH 7.4) (Merck Ltd. Lutterworth, Leics, UK) 
2) 2.5% sodium azide (Sigma, Dorset, UK) 
3) Benzyl penicillin 600 U/ml 
4) Streptomycin sulphate 100 mg/ml 
5) 2000 U/ml Kallikrein inactivator Aprotinin (Trasylol, Bayer UK Ltd, Newbury, UK) 
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6) 0.3M Sodium chloride (Merck Ltd. Lutterworth, Leics, UK) 
7) Sodium bromide (Merck Ltd. Lutterworth, Leics, UK) 
8) Visking tubing 
9) 0.15M Phosphate buffered saline (PBS pH 7.4) 
 
2.20.2. LDL isolation 
 
4ml of 0.2M disodium EDTA was mixed with 1ml of 2.5% sodium azide, 
0.125ml of benzyl penicillin (600 U/ml), 0.125ml streptomycin sulphate (100mg/ml), 
0.125ml of kallikrein inactivator aprotinin (200 U/ml) and 7ml of 0.3M sodium chloride. 
1ml of this preservative solution was added to universal tubes to prevent enzymatic 
degradation of lipoprotein particles.  
Venous blood (180ml) was then collected from normo-lipidaemic healthy 
volunteers who had undergone an overnight fast (20ml of blood was added into each 
universal container which had been pre filled with 1ml of the preservative solution). The 
plasma was separated by centrifugation at 3000g for 10 minutes. LDL (density range 
1.019-1.063g/ml) was isolated by ultracentrifugation in a Beckman L8-55 M or L8-80 M 
ultracentrifuge fitted with a 50.3 Ti rotor, using NaBr for density adjustment. The 
plasma was adjusted to a density of 1.019g/ml using formula 1 to calculate the amount 
of NaBr to be added and centrifuged at 40000rpm for 20 hours at 4oC to remove 
chylomicrons (CMs), very low-density lipoprotein (VLDL) and intermediate density 
lipoprotein (IDL). 
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Formula 1 
 
Amount of NaBr (g) to be added  =   vi    (df –di)  
 1 – [V x df] 
 
vi The initial volume 
di The initial density of plasma 
df Final density required 
V Partial specific volume of NaBr (0.235) 
 
Once the tubes had been removed from the rotor, they were placed on ice, the 
tube caps removed and the supernatant containing the VLDL and IDL aspirated and 
discarded using a 19 gauge needle attached to a 10ml syringe. The infranatants were 
pooled, mixed thoroughly and adjusted to a density of 1.063g/ml by adding NaBr using 
formula 1. The tubes were then re-capped and centrifuged at 40000rpm at 4oC for a 
further 20 hours to obtain LDL, which could be visualised as an orange layer at the top 
of the tube. LDL was harvested using a 19 gauge needle attached to a 10ml syringe, 
concentrated and purified by centrifugation at 40000rpm at 4oC for a further 20 hours. 
The LDL was harvested, placed within a dialysis membrane which had been softened by 
boiling in distilled water, and dialysed in 5 L of PBS containing 1mM EDTA for 24 
hours, changing dialysate twice. The EDTA acts as a chelating agent to sequester metal 
ions. Twenty four hours prior to the start of an oxidation experiment, a portion of the 
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LDL was re-dialysed as described above but omitting the EDTA. LDL protein 
concentration was measured using a Lowry assay as modified by Markwell et al (see 
above) (Markwell, Haas et al. 1978). 
 
2.20.3. Agarose gel electrophoresis of lipoproteins 
 
Native and oxidised LDL samples were separated by electrophoresis according 
to their net charge at pH 8.6 using low voltage electrophoresis (Noble 1968). Separated 
lipoproteins were stained using Fat Red 7B. The electrophoretic mobility of each sample 
was compared to that of a native LDL standard and the results expressed as relative 
electrophoretic mobility (REM). 
 
 
2.20.3.1. Materials 
 
1) Barbitone buffer (0.05 mol/L pH 8.6) Sodium barbital 8.85g/L, barbital 1.3g/L, 
sodium chloride 0.5g/L, sodium EDTA 0.35g/L. All chemicals are Analar grade (BDH 
Ltd, Dorset, UK) 
2) Pre-prepared agarose gels (10g/L) catalogue number 470100 (Ciba-Corning, UK) 
3) Fat Red 7B stain (Sigma, Dorset, UK) 
4) Methanol (Rathburn chemicals, UK) 
5) Distilled water 
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2.20.3.2. Preparation of reagents 
 
Barbitone buffer (2L) was prepared, pH adjusted to 8.6 and stored at 4oC for up 
to 4 months. A stock solution of Fat Red 7B stain (0.225g/l) was prepared by stirring 
0.045g of the stain in 100ml methanol in a conical flask for approximately 6 hours. 
Immediately prior to use, a working stain solution was prepared by adding 2ml of 
distilled water to 10ml of stain in a clean dry measuring cylinder. A de-stain was 
prepared by mixing methanol with water (2:1). 
 
2.20.3.3. Agarose gel electrophoresis 
 
The agarose film was gently peeled away from its backing plate and placed on a 
level surface. The wells were filled with approximately 0.8μl of sample or reference 
control. Both the anode and cathode chambers of the Ciba-Corning electrophoresis tank 
were filled with 100ml barbitone buffer and the gel placed in the holder and then 
lowered into the buffer. The sample origin was placed on the cathode side as the samples 
migrated towards the anode.  
The electrophoresis chamber was plugged into the power pack and 
electrophorised at a voltage of 100mV with a current of 4mA for 40 minutes. The 
progress of the electrophoresis was followed by the movement of the tracking dye 
(bromophenol blue). When electrophoresis was complete, the gel was removed from the 
chamber and dried in an oven at 55oC for 20 minutes. The gel was then placed in a 
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staining tray and stained for 1-4 minutes with freshly prepared working stain, in order to 
visualise the bands. The gel was then de-stained in methanol:water (2:1 v/v) and the 
backing on the gel was wiped and dried in an oven for 20 minutes. 
 
2.21. LDL ACETYLATION 
 
LDL was acetylated by incubation with saturated sodium acetate solution at a 
ratio of 1:2 and stirred continuously for 30 minutes at 4oC. Aliquots of acetic anhydride 
(1.5 μl/mg LDL) were added to the mixture over 90 minutes. The Ac-LDL was then 
dialysed against PBS containing 0.01% EDTA, pH 7.4, using a PD10 Column 
(Amersham). Freshly isolated native LDL and Ac-LDL were then passed through a 0.2 
μm filter and protein concentrations were measured using a modified Lowry method 
(Lowry OH 1951). Acetylation of LDL was confirmed by assessing the changes in 
mobility of modified lipoprotein using agarose gel electrophoresis.  
 
2.22. LDL OXIDATION BY MESANGIAL CELL MATRIX 
 
Relative electrophoretic mobility was used to assess oxidation of LDL by matrix 
(Wheeler, Chana et al. 1994). Matrix (500 μg/ml) and native LDL (250 μg/ml) were co-
incubated in the absence of cells. As a positive control, native LDL (250 μg/ml) was 
incubated in the presence of CuSO4 (10 μM). Native LDL co-incubated with BSA (500 
μg/ml) and native LDL alone served as negative controls. The effect of the antioxidants 
EDTA (100 μM) and butylated hydroxytoluene (BHT, 20 μM) on matrix co-incubated 
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with LDL was also assessed. Following incubation for 24 hours at 37oC, 5% CO2, the 
protein fraction was adjusted to 50 μg/ml with PBS and 5 μl of each sample was loaded 
on to a 0.5% agarose gel (Paragon Lipogel, Beckman, Austria) and subjected to 
electrophoresis. Bands were visualised by staining gels according to the manufacturer’s 
instructions.  
 
2.23. ANALYSIS OF SCAVENGER RECEPTOR-A ACTIVITY 
 
Based on previous experiments, THP-1 monocytic cells (1.5 x 106 cells/ml) were 
resuspended in supplemented RPMI medium and incubated with 500 μg/ml of 
solubilized matrix or with 500 μg/ml BSA protein (negative protein control) or 125nm 
PMA for 48 hours at 37oC. Cells were then exposed for a further 3 hours to 10 μg/ml 
Ac-LDL labelled with 1,1’-dioctadecyl-3,3,3’3’-tetramethyllindocarbocynanine 
perchlorate (Dil-labelled Ac-LDL, Biogenesis, Poole, UK) in the presence or absence of 
an excess of unlabelled Ac-LDL (250 μg/ml) to confirm the specificity of receptor-
mediated uptake. After incubation, the cells were recovered by centrifugation at 350 x g 
for 5 minutes, washed three times with PBS and fixed in 5% formalin solution in PBS. 
Ac-LDL binding and uptake was assessed by flow cytometry (EPICS XL-MCL; 
Beckman Coulter, Bucks, UK). Forward and side scatter gates were established to 
exclude dead cells and cell debris from the analysis. Fluorescence signals from the 
accumulated Dil associated with the cells were detected at 555-600 nm by a 
photomultiplier, and then converted to digital format and processed. The mean 
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fluorescence intensity (MFI) of 5 x 103 cells were analysed in each sample. Auto-
fluorescence signals generated by unlabelled cells were used as negative controls in each 
experiment. The MFI of the Dil-labelled cells was calculated by subtracting the auto-
fluorescence intensity from the observed MFI of labelled cells. Each experiment was 
carried out in duplicate, on four separate occasions with different preparations of cells 
and Ac-LDL. The average of the duplicate determinations was used for statistical 
analysis. 
 
2.24. MORPHOLOGICAL EXAMINATION OF FUNCTIONAL SCAVENGER RECEPTORS 
 
THP-1 monocytes were incubated in chamber slides (0.5 x 106 cells/ml) with 
solubilized matrix (500 μg/ml). PMA (125 nM) and BSA (500 μg/ml) served as positive 
and negative controls respectively. Polyinosinic acid (poly I) (100μg/ml) was also added 
as an inhibitor of the scavenger receptor. After 120 hours incubation at 37oC, cells were 
further incubated with 50 μg/ml Ac-LDL for 48 hours. Cells were then washed with 
PBS, fixed for 30 minutes with 5% formalin solution in PBS, stained with Oil Red O for 
30 minutes and counter-stained with haematoxylin for another 5 minutes. Lipid 
inclusion was assessed by observing at least 8 fields under a light microscope.  
 
 
2.25. STAINING OF HUMAN KIDNEY BIOPSY MATERIAL FOR MACROPHAGE 
ACTIVATION MARKERS 
 
Ethical approval to use human kidney biopsy material was obtained. Sections of 
formalin-fixed paraffin embedded kidney tissue were dewaxed and treated with 
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hydrogen peroxide to block endogenous peroxidase. Four kidney samples from patients 
with non-inflammatory conditions (two with ischaemic nephropathy, one with thin 
membrane nephropathy and one with myoglobinuria) and five from patients with 
inflammatory diseases (three with pauci-immune necrotizing/vasculitic 
glomerulonephritis, one with anti-glomerular basement membrane antibody disease and 
one with lupus nephritis) were submitted to Mr. James Gaya who then conducted 
staining for macrophage activation markers. Sections were then heated in TRIS-EDTA 
buffer (pH 9.0) before being stained with either a mouse monoclonal antibody to CD68 
diluted 1:200 (PG-M1 antibody, Dako, Cambridge UK), a mouse monoclonal antibody 
to PPARγ diluted 1:100 (Santa Cruz), or a goat antibody to scavenger receptor diluted 
1:500 (Abcam, Cambridge UK). In the case of the anti-CD68 antibody, samples were 
pre-treated with trypsin for 10 minutes. After incubation with the first stage antibody for 
1 hour, an Envision kit (Dako) was used for the second stage in the case of the mouse 
antibodies and a peroxidase-conjugated rabbit anti-sheep antibody in the case of the goat 
antibody. Hydrogen peroxide and diaminobenzidine were used as substrates and sections 
were counterstained with haematoxylin. 
 
2.26. DATA ANALYSIS 
 Groups of data in all experiments were evaluated for significance using a Mann-
Whitney unpaired non-parametric two tailed test or where indicated by paired student’s 
t-test. Results are expressed as mean + SEM unless otherwise stated and p < 0.05 was 
considered significant.
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CHAPTER 3 
MONOCYTE ADHESION TO MESANGIAL MATRIX 
MODULATES CYTOKINE AND METALLOPROTEINASE 
PRODUCTION 
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3.1. INTRODUCTION  
 
Blocking signalling pathways that determine monocyte/macrophage function 
represents an attractive target for therapeutic intervention. Such strategies have been 
evaluated in animal models of acute glomerulonephritis. For example monoclonal 
antibodies directed against leukocyte functional associated molecule-1 (LFA-1) and its 
endothelial ligand, intercellular adhesion molecule-1 (ICAM-1) were found to block 
monocyte trafficking and inhibit glomerular injury in rats given nephrotoxic serum 
(Kawasaki, Yaoita et al. 1993). In the same model, blocking antibodies directed against 
another monocyte integrin, very late antigen-4 (VLA-4), also attenuated renal injury but 
without affecting the number of infiltrating cells, whilst blockade of vascular cell 
adhesion molecule-1 (VCAM-1), a major ligand of VLA-4, had no effect (Allen, 
McHale et al. 1999). These results suggest that binding of VLA-4 to a ligand other than 
VCAM-1 within the glomerulus may be important in modulating monocyte function in 
the context of glomerular injury. Previous studies by our group demonstrated that 
adhesion of monocytes to activated mesangial cells was mediated, at least in part, by 
cell-associated fibronectin (Chana and Wheeler 1999). It was postulated that this matrix 
component may be an important VLA-4 ligand. The following experiments were 
designed to test the hypothesis that interactions with mesangial matrix modulates the 
secretory function of monocyte/macrophages. The results indicate that matrix may 
promote mononuclear cell accumulation within the mesangium, and that interactions 
between monocytes (in part mediated by VLA-4) and matrix components (particularly 
fibronectin) promote secretion of monocyte products that may modify disease outcome. 
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3.3. RESULTS 
 
3.3.1. Matrix composition 
 
Staining studies demonstrated that after solubilization of mesangial cells, no 
nuclear material remained and that fibronectin was present in the residual matrix. 
Electron microscopy confirmed an absence of cellular debris (Figure 3.1A). In keeping 
with previous published work, pre-stimulation of mesangial cells with TGF-β alone and 
in combination with TNFα led to increased fibronectin production (Pawluczyk and 
Harris 1998). At a concentration of 10 ng/ml, exposure to TGF-β increased cell-
associated fibronectin to (mean ± SEM)) 127.8% ± 10.1% (p < 0.05) compared to 
control cells grown in serum-free medium (100%). The cell-associated fibronectin was 
further increased to 256.7% (3.9%, p < 0.001) when a combination of 10 ng/ml of TNFα 
and 10 ng/ml TGF-β was added suggesting that these cytokines had a synergistic effect 
on matrix synthesis. TNFα alone had little effect on cell-associated fibronectin 
production (114.5% + 4.1%, p = NS). When matrix is assessed for cytokine entrapment, 
it was found to contain very low concentrations of TGF-β ( <0.05 pg/μg), and virtually 
undetectable amounts of TNFα ( <0.02 pg/μg), IL-1β ( <0.003 pg/μg) and IL-6 ( <0.003 
pg/μg). 
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3.3.2. Monocyte characteristics 
  
U937 and peripheral blood-derived monocytes recovered after 24 hours 
incubation on tissue culture plastic plates possessed both early (CD 69) and late (HLA-
DR) monocyte surface markers. There was no change in the expression of either cell 
marker, even after the cells were cultured on matrix or plastic for up to 72 hours.  
 
3.3.3. Adherence of monocytes to mesangial cell matrix 
 
Both U-937 and peripheral blood-derived monocytes adhered strongly to matrix 
synthesized by mesangial cells grown under standard conditions, following the removal 
of the mesangial cells (Figure 3.1B). Binding occurred predominantly to the matrix 
itself, with minimal adhesion to the uncoated plastic plate determined by subtracting 
background staining to plastic alone. Using U937 cells it was demonstrated that pre-
stimulation of mesangial cells with TGF-β and TNFα led to increased monocyte binding 
to the residual matrix (Figure 3.2). Compared to control matrix (i.e. that produced by 
mesangial cells exposed to serum free medium alone, 100% binding), binding of U937 
cells to matrix synthesized by cells pre-stimulated with TGF-β and TNFα was increased 
by 127.5% ± 17.7%, (p < 0.05) and 123.6% ± 9.7% (p < 0.05) respectively. When a 
combination of the two cytokines was used, binding increased to 188.0% ± 5.5% (p < 
0.001) compared to control matrix. 
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Figure 3.1.  
 
(A) Electron micrograph of mesangial matrix. The cell layer was removed from the 
underlying matrix by adding 2.5mM NH4OH and 0.1% Triton X-100. The matrix was 
then fixed and prepared for electron microscopy as described in the methods section.  
Bar = 1 μm, original magnification X 5000.  
 
(B) U-937 monocytes adherent to cell matrix. U-937 monocytes were incubated with 
matrix for one hour. After washing, adherent monocytes were fixed and stained with 
crystal violet as described in the methods section and visualised under a light 
microscope. Original magnification X 100. 
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Figure 3.2. Adhesion of U-937 monocytes to matrix synthesized by mesangial cells 
prestimulated with TGF-β, TNFα and TGF-β/TNFα. Monocytes were incubated for 
one hour with matrix after removal of mesangial cells. Adherent monocytes were fixed, 
stained, solubilized and quantified by colorimetry. The mean (SEM) of triplicate 
absorbance readings, corrected for background staining of matrix, is expressed as a 
percentage of control (matrix arising from unstimulated cells). The results are 
representative of those obtained in 4 experiments. * p < 0.05, ** p < 0.001 vs. control.   
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3.3.4. Inhibition of monocyte adhesion to matrix 
 
Antibodies directed against VLA-4 and VLA-5 integrins reduced U937 
monocyte binding to mesangial matrix when compared to control (no antibody, 100%). 
Using non-prestimulated mesangial cells, anti-VLA-5 antibody reduced monocyte 
binding to 78.4% ± 6.0%, (p < 0.005) (Figure 3.3A) when compared to control matrix 
(no antibody, 100%). In contrast, binding to matrix synthesized by TGF-β/TNFα pre-
stimulated mesangial cells was reduced by anti-VLA-5 antibody to 44.8% ± 2.5% (p < 
0.0001) (Figure 3.3B). Once again, a reduction in binding was observed when matrix 
from non-prestimulated mesangial cells was primed with anti-VLA-4 antibody, but not 
with anti-fibronectin antibody (Figure 3.3A). Anti-VLA-4 and anti-fibronectin 
antibodies also reduced monocyte adhesion to matrix produced by TGF-β/TNFα pre-
stimulated mesangial cells to 54.9% ± 4.9% (p < 0.0001) and 56.6% ± 5.6% (p < 
0.0001), respectively, compared to control (Figure 3.3B). In a comparative experiment, 
binding of peripheral blood-derived monocytes to mesangial matrix synthesised by non-
prestimulated mesangial cells was inhibited by 61.5 ± 4.3% and 58.5 ± 3.6% by anti-
VLA-4 and anti-VLA-5 antibodies respectively. 
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Figure 3.3. Inhibition of U-937 monocyte adhesion to matrix produced by 
unstimulated mesangial cells (A) or mesangial cells prestimulated with TGF-
β/TNFα (B). The matrix was pre-incubated with anti-fibronectin (25 μg/ml) antibody for 2 
hours before a suspension of U-937 monocytes was added. Alternatively monocytes were pre-
incubated with anti-VLA-4 (10 μg/ml) and anti-VLA-5 (5 μg/ml) antibodies for 1 hour before 
being added to matrix. After washing, adherent monocytes were fixed, stained with crystal 
violet, solubilized and quantified by densitometry. The results are expressed as mean (SEM) 
absorbance, corrected for the background staining of matrix, and expressed as a percentage of 
control (100%). These results are a representative of 4 experiments; each conducted in triplicate 
at optimal antibody concentrations. * p <0.0001 vs. control.  
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3.3.5. Adhesion to mesangial matrix stimulates monocyte cytokine secretion 
 
Adhesion of peripheral blood-derived monocytes to mesangial matrix led to an 
increase in the production of IL-1β by 14-fold when compared to control monocytes 
incubated in plastic wells (7.74 + 1.25 pg/ml vs. 0.55 + 0.23 pg/ml, p < 0.001) (Figure 
3.4). In contrast, there was a 226-fold increase following LPS stimulation (124.7 + 15.26 
pg/ml, p < 0.001). Similar results were obtained when the production of IL-6 and TNFα 
was examined. There were approximately 37-fold and 6-fold increases in IL-6 and 
TNFα production by monocytes bound to matrix when compared to control cells 
incubated in plastic wells. These increases in cytokine levels cannot be attributed to the 
change in monocyte cell number. Proliferation studies using 3H-thymidine showed 
similar radiolabel incorporation into U-937 and peripheral blood-derived monocytes 
incubated on either matrix or plastic culture plates. 
Like whole matrix, individual matrix proteins stimulated cytokine production but 
differed in terms of the magnitude of this effect. For example, there was approximately a 
19-fold increase in IL-1β when peripheral blood-derived monocytes were incubated with 
fibronectin (100μg/ml, p < 0.005) when compared to control (monocytes incubated in 
plastic wells) (Figure 3.5A). In contrast, collagen type IV and laminin increased 
cytokine production by approximately 14- and 5-fold respectively. This compared to a 9-
fold increase when solubilized whole matrix was added at the same concentration. These 
proteins also stimulated monocyte IL-6 and TNFα secretion (Figure 3.5B and 3.5C) with 
a similar pattern of response. 
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Figure 3.4. IL-1β (Α), IL-6 (B) and TNFα (C) production by peripheral blood-
derived monocytes cultured in the presence of mesangial cell matrix. Peripheral 
blood-derived monocytes (0.5 x 106 cells/ml) were incubated with mesangial cell matrix for 24 
hours. For positive and negative controls, monocytes were incubated in plastic wells with or 
without 10 μg/ml LPS respectively. The resulting conditioned medium was collected, spun and 
cytokines measured by ELISA. Results are mean + SEM of 4 experiments, each performed in 
quadruplicate. * p <0.001 vs. control. 
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Figure 3.5. IL-1β (A) and IL-6 (B) and TNFα (C) production by monocytes 
cultured in the presence of soluble matrix and its protein components. PBMCs (0.5 x 
106 cells/well) were incubated with solubilized mesangial cell matrix (100 μg/well) or its protein 
components (100 μg/well) for 24 hours. For positive and negative controls, monocytes were 
incubated in plastic wells with or without 10 μg/ml LPS respectively. The resulting conditioned 
medium was collected, spun and cytokines measured by ELISA. Results (mean + SD) are 
representative of 4 experiments, each performed in quadruplicate. *p <0.005 vs. control.    
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3.3.6. Effects of antibodies on cytokine production  
 
The secretion of cytokines by peripheral blood-derived monocytes was mimicked 
by incubation with anti-integrin antibodies. For example, incubation of monocytes in 
plastic culture plates with anti-VLA-4 (10 μg/ml) and anti-VLA-5 (5 μg/ml) antibodies 
increased IL-1β production compared to control monocytes in medium alone (Table 
3.1). Similarly, TNFα secretion was increased by both antibodies when compared to 
control.  
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Table 3.1. Production of cytokines by human macrophages exposed to anti-VLA-4 
(10 μg/ml) and anti-VLA-5 (5 μg/ml) antibodies for 24 hours. 
 
 
Antibody IL-1β (pg/ml) p value TNFα (pg/ml) p value 
Control 2.0 + 2.4 - 64.2 + 6.0 - 
anti-VLA-4 45.4 + 12.0 <0.005 2649.6 + 424.2 <0.0001 
anti-VLA-5 93.3 + 13.5 <0.0001 
<0.05* 
3551.7 + 458.4 <0.0001 
<0.005* 
 
 
Cytokines were measured in the conditioned medium by ELISA. Results are mean 
+SEM of 4 experiments, each performed in triplicate or quadruplicate. Statistical 
analysis was performed using a paired student’s t-test. p vs. control. *p vs. anti VLA-4. 
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3.3.7. Mesangial cell matrix stimulation of MMP release 
 
Incubation with mesangial matrix resulted in increased peripheral blood-derived 
monocyte MMP-9 secretion (Figure 3.6A). Densitometric analysis showed a significant 
2.4-fold rise in MMP-9 activity compared to control (Figure 3.6B). In contrast, matrix 
had no effect on the release of monocyte MMP-2 (data not shown). Addition of matrix 
proteins also led to increased activity of monocyte MMP-9. The response to fibronectin 
was dose-dependent (Figure 3.7).  
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Figure 3.6. Matrix metalloproteinase (MMP) released by monocytes cultured in the 
presence of mesangial cell matrix (A). Peripheral blood-derived monocytes (0.5 x 106 
cells/ml) were incubated with mesangial cell matrix for 24 hours in the absence of foetal 
calf serum. For controls, monocytes were incubated in plastic wells with or without 10 
μg/ml LPS. The resulting conditioned medium was collected, spun and analyzed by 
zymography. Lane 1, control; Lane 2, cell matrix; Lane 3, LPS. Results are 
representative of 5 experiments. Densitometric evaluation of zymograms (B) shows the 
relative change in metalloproteinase secretion compared to control (100%). 
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Figure 3.7. Matrix metalloproteinase (MMP) release by monocytes cultured in the 
presence of fibronectin (A). Peripheral blood-derived monocytes (0.5 x 106 cells/ml) 
were co-incubated with increasing concentrations of fibronectin for 24 hours in the 
absence of foetal calf serum. The resulting conditioned medium was subjected to 
zymography. Results are representative of 2 experiments. Densitometric evaluation of 
zymograms (B) shows the relative change in metalloproteinase secretion compared to 
control (100%). 
 96
3.3.8. Effect of matrix and soluble proteins on monocyte TIMP secretion 
 
Matrix did not stimulate peripheral blood-derived monocyte TIMP I or TIMP II 
secretion (Table 3.2), nor was there any effect seen with addition of fibronectin (data not 
shown). The effect of anti-VLA-4 and anti-VLA-5 antibodies on monocyte secretion of 
metalloproteinases or their inhibitors was not investigated. 
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Table 3.2. Release of tissue inhibitors of metalloproteinases by human macrophages 
incubated on plastic culture plates (control), with mesangial cell matrix, and LPS 
for 24 hours. 
 
 TIMP I (ng/ml) TIMP II (ng/ml) 
Control 16.7 + 3.8 848.1 + 126.0 
Matrix 14.3 + 1.3 725.5 + 102.1 
LPS 22.5 + 1.4 630.3 + 99.3 
 
 
TIMP I and II were measured in the conditioned medium by ELISA as described in the 
methods section. Results are mean + SEM of 4 experiments (TIMP I) and 3 experiments 
(TIMP II) each performed in quadruplicate.  
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3.4. DISCUSSION 
 
This study demonstrates that monocytes specifically bind to mesangial matrix 
and to its component proteins including fibronectin and to a lesser extent collagen type 
IV and laminin. Monocyte binding to whole matrix is mediated, at least in part by 
fibronectin. An increase in monocyte binding to mesangial matrix was shown to 
accompany the enhanced synthesis and secretion of fibronectin induced by cytokine pre-
stimulation of mesangial cells. Incubation of monocytes with mesangial matrix and 
individual matrix proteins led to the secretion of pro-inflammatory cytokines (IL-1β, IL-
6, and TNF-α) and to the activation of metalloproteinase (MMP-9). The release of 
MMP-9 was not associated with a change in production of tissue inhibitors of 
metalloproteinase indicating a net breakdown of matrix, thus exposing an increased 
potential for the binding of infiltrating monocytes. By adding radiolabelled thymidine to 
monocytes incubated with mesangial matrix it was possible to demonstrate that this 
increased secretion of cytokines and metalloproteinase was not associated with cell 
proliferation. These results therefore suggest that accumulation of mesangial matrix, 
particularly fibronectin, promotes monocyte entrapment and that binding to matrix 
proteins specifically stimulates monocyte secretion of inflammatory cytokines and 
matrix degrading metalloproteinase. Such interactions may have important implications 
in the pathogenesis of renal injury, particularly because the mechanisms by which 
macrophages are activated is known to determine their functional characteristics (Song, 
Ouyang et al. 2000). 
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Binding of monocytes to fibronectin is likely to be mediated by integrin 
receptors which are composed of the α and β subunits (Hynes 1992). Among these 
integrins, α4β1 (VLA-4) which binds to the CS1 and CS-5 regions of the IIICS domain 
of the fibronectin (Humphries, Komoriya et al. 1987; Mould, Komoriya et al. 1991) and 
α5β1 (VLA-5) which binds to the RGD sequence (Brown and Goodwin 1988; Brown, 
Phillips et al. 1989) are found on activated monocytes (Ferreira, Garcia-Pardo et al. 
1990; Hemler, Elices et al. 1990). The possible involvement of VLA-4, and VLA-5 was 
therefore investigated. Anti-VLA-4 and VLA-5 antibodies caused a marked inhibition of 
U937 and peripheral blood-derived monocyte adhesion to whole matrix, suggesting that 
both cells shared common binding mechanisms involving both integrins. However, 
neither antibody completely blocked the adhesion process thereby indicating that other 
integrins and matrix components including collagen and laminin may participate in this 
interaction. The demonstration of a common binding mechanism allowed us to use U937 
cells, which were more readily available than peripheral blood-derived monocytes, for 
binding studies although the latter were employed to examine the effects of binding on 
secretory function.  
Chronic glomerular diseases are characterised by the accumulation of 
extracellular matrix composed of proteins including collagens, laminin and fibronectin 
along with proteoglycans and glycosaminoglycans. In the healthy glomerulus, these 
components not only provide structural support for glomerular cells but also influence 
their behaviour (Border, Okuda et al. 1989). Fibronectin, one of the most abundant 
mesangial matrix proteins, has been shown to have chemotactic properties for 
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monocytes, macrophages and fibroblast, and to be mitogenic to fibroblasts and 
mesangial cells (Ruoslahti 1988). Since these results demonstrate that individual matrix 
components differ in their ability to bind and activate macrophages, it follows that the 
nature of disease-related changes in matrix composition might in turn influence the 
extent of macrophage accumulation within the diseased glomerulus and the secretory 
characteristics of these infiltrating cells. Such interactions could determine the outcome 
of an acute or chronic inflammatory process.  
Several animal and human studies suggest that monocytes/macrophages play a 
critical role in the initiation and progression of renal diseases. For example, in rats with 
remnant kidneys, macrophage accumulation was shown to strongly correlate with the 
progression of focal sclerosis suggesting that these cells may play a role in the scarring 
process (van Goor, Fidler et al. 1991). In humans, monocyte accumulation is seen in 
most forms of glomerulonephritis, including those associated with progressive fibrosis 
(Magil and Cohen 1989; Li, Hancock et al. 1990). Whilst monocyte infiltration may 
have beneficial functions, for example, promotion of the resolution of inflammation by 
apoptosis of infiltrating cells (Duffield, Erwig et al. 2000; Huynh, Fadok et al. 2002), 
several monocyte/macrophage secretory products may have a detrimental influence on 
the function of adjacent mesangial cells. These results demonstrate that binding of 
monocytes to whole matrix and matrix proteins, particularly fibronectin, enhances 
secretion of proinflammatory cytokines and matrix degrading metalloproteinases. These 
findings are in agreement with those of other investigators who have reported enhanced 
monocyte secretion of IL-1, IL-6, IL-8 and TNFα upon exposure of cells to matrix 
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proteins including fibronectin (Haskill, Johnson et al. 1988; Heinel, Singleton et al. 
1995; Mahnke, Bhardwaj et al. 1995; Takizawa, Nishinarita et al. 1995). For example, 
Takizawa et al demonstrated that addition of fibronectin to monocytes isolated from 
human plasma stimulated production of IL-1, IL-6 and TNFα (Takizawa, Nishinarita et 
al. 1995). There have also been reports of matrix proteins modulating secretion of 
metalloproteinases by various cells including fibroblast (Huhtala, Humphries et al. 1995) 
and keratinocytes (Larjava, Lyons et al. 1993). Studies by Martin et al have 
demonstrated that specific matrix components enhance secretion of MMP-2 and MMP-9 
by human mesangial cells and that membrane type metalloproteinase MTMMP, which is 
selectively induced by fibronectin, is important in this process (Martin, Eynstone et al. 
2001). The present study extends these findings by demonstrating that matrix produced 
by glomerular cells may also modulate the accumulation and activation of infiltrating 
inflammatory cells. Matrix-mediated effects may help to explain the changes in 
metalloproteinase to inhibitor ratios observed by Mené et al in co-culture experiments 
involving mesangial cells and monocytes (Mene, Caenazzo et al. 2001). 
 Since binding of both U937 and peripheral blood-derived monocytes to 
mesangial matrix components involved the integrins VLA-4 and VLA-5, an 
investigation into whether these molecules might be involved in signal transduction was 
carried out. Stimulation of peripheral blood-derived monocytes with either anti-VLA4 or 
anti-VLA5 antibodies mimicked the effects of matrix on cytokine production, as well as 
blocking monocyte binding to matrix. Studies in other cell types have shown similar 
effects, for example, activation of fibroblasts by a crosslinking anti-ICAM-1 antibody 
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(Clayton, Evans et al. 1998) and of fibrosarcoma cells by antibodies to α5, α6 and β1 
integrin subunits (Stanton, Gavrilovic et al. 1998) was associated with activation. Whilst 
the down stream events were not investigated in this study, in other experimental 
settings the binding of integrin components to matrix induces activation of 
phospholipases (Cybulsky, Carbonetto et al. 1993), kinase signalling pathways (Malik 
and Parsons 1996) and the AP-1 transcription factor (Yamada, Nikaido et al. 1991). 
Thus it is reasonable to propose that infiltrating monocytes may be activated by 
interactions with matrix components via integrin receptors. Monocyte responses may be 
influenced by pre-programming as has been observed following exposure to a variety of 
cytokines (Erwig, Kluth et al. 1998; Erwig, Stewart et al. 2000; Song, Ouyang et al. 
2000). Furthermore accumulation and disease-specific modification of matrix 
components may alter monocyte/macrophage behavior and thereby potentially influence 
disease outcome. For example, these results would suggest that accumulation of 
fibronectin enhances metalloproteinase production, without increased inhibitor activity, 
a situation that is likely to promote matrix degradation. Inhibition of monocyte responses 
by blockade of these signalling pathways represents a potential target for therapeutic 
intervention in human glomerular disease and has proved effective in recent animal 
studies (Allen, McHale et al. 1999). 
In summary, these results demonstrate that mesangial matrix plays a key role in 
the immobilization and activation of monocytes within the glomerulus. Since matrix 
proteins differ in their ability to modulate monocyte secretory functions, changes in 
matrix composition or organization in glomerular disease may influence the behavior of 
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infiltrating cells and thereby the outcome of the disease process. Better understanding of 
the potential importance of these processes may help in the design of treatment strategies 
for chronic glomerular diseases.
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CHAPTER 4 
MESANGIAL MATRIX-ACTIVATED MONOCYTES 
EXPRESS FUNCTIONAL SCAVENGER RECEPTORS 
AND ACCUMULATE INTRACELLULAR LIPID 
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4.1. INTRODUCTION 
 
Transendothelial migration of monocytes into the glomerular mesangium is a 
recognized early feature of glomerular injury in man and in experimental models of 
kidney disease (Brady 1993). These cells play a central role in orchestrating tissue 
inflammation and may be critical in determining whether the final outcome of an acute 
inflammatory glomerular lesion is complete resolution or permanent scarring (Duffield 
2003). Interactions between monocytes and extracellular structures encountered during 
the process of transmigration may play a critical role in determining the phenotype and 
therefore the behaviour of the activated tissue macrophage. As described in section 1.3, 
extracellular matrix is a highly ordered network of fibrous proteins and associated 
glycoproteins embedded in a hydrated ground substance of glycosaminoglycans and 
proteoglycans. It is recognised that matrix not only provides a structural framework, but 
also influences cellular behaviour. For example, integrin-mediated adhesion of 
monocytes to extracellular matrix may regulate expression of numerous inflammatory 
and immune response genes (de Fougerolles and Koteliansky 2002). The importance of 
this process is demonstrated by disease states thought to arise from dysregulation of 
matrix-integrin interactions (Campbell, Senior et al. 1987).  
In the previous chapter, it has been demonstrated that exposure of human 
monocytes to both intact glomerular matrix (and to its individual components) enhanced 
the production of a range of inflammatory cytokines and matrix-degrading 
metalloproteinases. However, these experiments did not conclusively demonstrate that 
such interactions induced monocyte to macrophage differentiation. The experiments 
 106
described in this chapter were designed to test the hypothesis that activation by 
mesangial matrix converts monocytes to a macrophage phenotype. The expression of 
three macrophage specific markers were studied: a) the peroxisomal proliferator-
activated receptor-γ (PPAR−γ), a nuclear receptor that acts as a transcriptional mediator 
for genes involved in lipid metabolism and adipogenesis (Moore, Rosen et al. 2001), b) 
CD36, a class B scavenger receptor and c) scavenger receptor class-A. Both these 
scavenger receptors are located in the plasma membrane of the macrophage and are 
involved in the cellular uptake of modified lipoproteins (Brown, Basu et al. 1980). Since 
unregulated uptake of modified lipoproteins is a characteristic of the tissue macrophage, 
the capacity of matrix-activated monocytes to accumulate intracellular lipid when 
exposed to acetylated low density lipoprotein (Ac-LDL), a scavenger receptor ligand 
was also tested. To further examine the role of matrix in foam cell formation, an 
assessment of the capacity of matrix to modify LDL in the absence of cells to produce 
oxidised LDL (ox-LDL), a naturally occurring scavenger receptor ligand identified in 
diseased glomeruli, was conducted. To confirm the relevance of these observations to 
human glomerular disease, human kidney biopsy sections from patients with 
inflammatory and non-inflammatory glomerular disease were stained for macrophage 
activation markers. These results demonstrate that mesangial cell matrix has the 
potential both to induce monocyte to macrophage maturation and to oxidise LDL, 
thereby indicating a likely modulatory role in glomerular inflammation and foam cell 
formation. It was also possible to demonstrate activated macrophages in glomeruli 
derived from patients with inflammatory glomerular disease.  
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4.3. RESULTS 
 
4.3.1. PPAR-γ expression by matrix-activated monocytes 
 
Whilst no PPAR-γ mRNA was detected by RT-PCR analysis of total RNA 
extracted from freshly isolated THP-1 monocytes, message was detectable within 24 
hours when cells were incubated with soluble mesangial matrix (500 μg/ml). Expression 
was maximal at 48 hours, persisting over at least 5 days and was comparable to that 
observed when cells were stimulated with PMA over a similar time period under 
identical experimental conditions (Figure 4.1). Increased expression of PPAR-γ protein 
within 24 hours of exposure of matrix stimulation was confirmed by Western analysis, 
with levels of expression being similar to those observed following PMA stimulation 
(Figure 4.2). No further increase in expression was observed when incubation was 
extended beyond 48 hours to 7 days.  
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Figure 4.1. Time-dependent expression of PPAR-γ mRNA by THP-1 monocytes. 
Monocytes were incubated with mesangial cell matrix (500 μg/mL) or PMA (125 nM) 
for up to 120 hours. A) PPAR-γ mRNA expression was examined by RT-PCR. B) 
Histogram showing analysis of mean ± SEM density of bands of PPAR-γ mRNA from 4 
experiments, normalised by subtracting BSA protein control and comparison with β-
actin mRNA. 
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Figure 4.2. Western analysis of PPAR-γ protein expression by THP-1 monocytes. 
Monocytes were incubated with 500 μg/mL mesangial cell matrix or PMA (125nM) for 
0, 6, 24 and 48 hours. Cells were lysed and subjected to SDS-PAGE and proteins 
transferred to nitrocellulose membrane. A) Western blot showing PPAR-γ detected using 
an anti-PPAR-γ antibody. B) Histogram showing mean ± SEM density of bands of 
PPAR-γ protein from quadruplicate wells, normalised by comparison with α-actin 
protein, and expressed as percentage of control (0 hours). *p<0.005 vs. Control. 
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4.3.2. CD36 expression by matrix-activated monocytes 
 
Enhanced expression of CD36 mRNA was detected by RT-PCR analysis of total 
RNA extracted from THP-1 monocytes exposed to soluble mesangial matrix (500 
μg/ml). An increase in message was detected after 48 hours of incubation, and was 
comparable with that observed when cells were stimulated with PMA for the same time 
period under identical experimental conditions (Figure 4.3). No further increase in 
expression was observed when incubation was extended beyond 120 hours to 7 days 
(data not shown). 
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Figure 4.3. Time-dependent expression of CD36 mRNA in response to mesangial 
matrix. 
Mesangial cell matrix (500 μg/mL) or PMA (125 nM) were incubated with monocytes 
for 0, 6, 48 and 120 hours. A) RT-PCR analysis of CD36 mRNA expression. B) 
Histogram showing analysis of mean ± SEM of CD36 mRNA bands from 4 
experiments, normalised by subtracting BSA protein control and comparison with β-
actin mRNA. Results are expressed as a percentage of control (0 hours). *p<0.005 vs. 
control. 
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4.3.3. Scavenger receptor expression by matrix-activated monocytes 
 
Scavenger receptor-A mRNA expression increased in a concentration-dependent 
manner when THP-1 monocytes were incubated with increasing concentrations of 
soluble matrix protein for 48 hours with a maximal response at 100 μg/ml (Figure 4.4). 
A time-dependent increase was observed with addition of 500 μg/ml matrix protein 
increasing up to 120 hours incubation (Figure 4.5), with no further change up to 7 days 
(data not shown). No expression was observed under baseline conditions prior to 
stimulation, neither did equivalent concentrations of BSA induce detectable scavenger 
receptor-A message, suggesting that the observed effect was specific.  
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Figure 4.4. Scavenger receptor A mRNA expression by THP-1 monocytes 
incubated in the presence of increasing mesangial matrix for 48 hours. 
Monocytes were incubated with increasing mesangial cell matrix concentrations of 0-
500 μg/mL or PMA (125 nM) for 48 hours. A) Scavenger receptor A mRNA expression 
examined by RT-PCR. B) Histogram of mean ± SEM density of scavenger receptor A 
mRNA bands from 4 experiments, normalised by comparison with β-actin mRNA, and 
expressed as percentage of results obtained when equal amounts of BSA were added. 
*p<0.005 vs. equivalent BSA control. 
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Figure 4.5. Time-dependent expression of scavenger receptor A mRNA in response 
to mesangial matrix. 
Mesangial cell matrix (500 μg/mL) or PMA (125 nM) were incubated with monocytes 
for 0, 6, 48 and 120 hours. A) RT-PCR analysis of scavenger receptor A mRNA 
expression. B) Histogram of mean ± SEM density of scavenger receptor A mRNA bands 
from 4 experiments, normalised by subtracting BSA protein control and comparison 
with β-actin mRNA. Expressed as a percentage of control (0 hours). *p<0.005 vs. 
control. 
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4.3.4. Uptake of modified lipoproteins by matrix-activated monocytes 
 
The presence of functional scavenger receptors was confirmed using flow 
cytometry in which incubation of matrix-activated monocytes with Dil-labelled Ac-LDL 
led to an increase in mean fluorescence intensity (MFI) (Figure 4.6). This effect was 
largely reversed by addition of an excess of unlabelled ligand. The MFI of THP-1 cells 
incubated with Dil-labelled Ac-LDL after exposure to matrix increased to 373±34.8% 
(p<0.005) as compared to cells exposed to BSA (100%). PMA pre-stimulation of 
monocytes, increased MFI to 423±55.5% (p<0.005). These increases in MFI induced by 
matrix-and PMA activation were inhibited by the addition of excess unlabelled Ac-LDL 
to 134±12.1% (p<0.001 vs. no excess of unlabelled lipoprotein) and to 170±16.1% (p 
<0.001) respectively, suggesting specific binding of Dil-labelled Ac-LDL to scavenger 
receptors.  
Incubation of monocytes with unlabelled Ac-LDL following stimulation by 
exposure to matrix for 120 hours led to intracellular accumulation of Oil Red O- stained 
lipid droplets (Figure 4.7A). Lipid uptake did not occur following BSA stimulation 
(Figure 4.7B). Prior exposure to PMA was also associated with intracellular lipid 
deposition but no intracellular lipid staining was observed when poly I was added with 
Ac-LDL following activation of monocytes by matrix or PMA.  
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Figure 4.6. Effects of matrix on Ac-LDL uptake by monocyte/macrophages. 
THP-1 monocytes were incubated with matrix (500 μg/mL) for 48 hours. BSA (500 
μg/mL) and PMA (125 nM) served as negative and positive controls, respectively. 
Monocytes were recovered and incubated for a further 3 hours with 10 μg/mL DiI-
labelled Ac-LDL in the presence or absence of an excess (XS) of unlabelled Ac-LDL 
(250 μg/mL). The mean fluorescence intensity (MFI) was calculated by subtracting the 
auto-fluorescence intensity from the observed fluorescence intensity of labeled cells. 
The histogram represents mean ± SEM MFI calculated from 4 experiments under the 
conditions shown, carried out in duplicate and expressed as percentage above BSA 
control (100%). *p<0.005 vs. BSA control, **p<0.001 vs. no excess unlabelled Ac-
LDL. 
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Figure 4.7. Visualisation of Ac-LDL uptake by THP-1 monocytes following 
exposure to mesangial matrix. 
THP-1 monocytes were incubated with A) mesangial matrix (500 μg/mL) for 120 hours, 
or (500 μg/mL) for 120 hours, or B) BSA (500 μg/mL, negative control). The cells were 
then incubated with 50 μg/mL Ac-LDL for 48 hours at 37oC, fixed and examined for 
lipid inclusions by Oil Red O staining. The results shown are typical of those observed 
in 3 separate experiments. 
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4.3.5. Oxidation of LDL by mesangial cell matrix  
 
Incubation of LDL with mesangial cell matrix in the absence of cells led to 
enhanced electrophoretic mobility of recovered lipoprotein on agarose gel (Figure 4.8). 
A similar shift in mobility was seen when LDL was exposed to copper sulphate, a 
powerful oxidising agent, but was blocked when the antioxidants EDTA (100 μM) and 
BHT (20 μM) were added, suggesting that matrix induces LDL oxidation. In contrast, 
incubation with BSA did not change the electrophoretic mobility of the lipoprotein. 
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Figure 4.8. Agarose gel electrophoresis demonstrating oxidation of LDL by 
mesangial matrix. 
Lane 1: Freshly isolated native LDL (negative control), Lane 2: LDL incubated with 
BSA protein (500μg/mL), Lane 3: LDL incubated with CuSO4 (10 μM, positive 
control), Lane 4: Matrix (500μg/mL) incubated with LDL, Lane 5: Matrix incubated 
with LDL and with the antioxidants EDTA (100 μM) and BHT (20 μM). LDL incubated 
with mesangial matrix had a mobility similar to that observed with the positive control 
(CuSO4). This effect was abolished by the addition of EDTA and BHT, indicating that 
matrix promotes LDL oxidation.  
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4.3.6. Identification of macrophage activation markers in human kidney biopsy 
material 
 
CD-68 positive cells were extremely difficult to identify in the normal kidney 
section and there was no staining for PPAR-γ or scavenger receptor. In contrast, all three 
markers were readily detected in the inflamed kidney, predominantly within the 
glomeruli (Figure 4.9). CD68 and scavenger receptor were located in a cytoplasmic 
distribution and PPAR-γ within nuclei in keeping with the cellular location of these 
markers.  
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Non-inflamed: CD68     Inflamed: CD68  
 
  
Non-inflamed: PPAR-γ    Inflamed: PPAR-γ  
 
  
Non-inflamed: Scavenger receptor   Inflamed: Scavenger receptor  
 
 
Figure 4.9. Staining of human kidney sections for macrophage activation markers.  
Sections of non-inflamed and inflamed human kidney were stained for the macrophage 
antigen CD-68 and for the activation markers PPAR-γ and Scavenger receptor. 
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4.4. DISCUSSION 
 
These results demonstrate that exposure of monocytes to mesangial cell matrix in 
vitro induces expression of PPAR-γ,  CD36 and scavenger receptor-A and promotes 
phagocytic activity, characteristics usually associated with a macrophage phenotype. 
This would suggest that conversion of infiltrating monocytes to mature tissue 
macrophages within the glomerular mesangium in vivo may not necessarily depend on 
the presence of mesangial cells, but may result from direct interactions with matrix 
components. While circulating monocytes are relatively inert, the activated tissue 
macrophage may take on a destructive role, inducing cell death by apoptosis and 
degrading extracellular matrix. Alternatively, these cells may facilitate repair by 
inducing cell proliferation and secretion of replacement matrix components (Duffield 
2003). Macrophages also play a key role in the phagocytosis of cellular debris, lipids 
and denatured proteins in inflamed tissue, a process that may result in the formation of 
foam cells. Foam cells are characteristically seen at sites of tissue injury, for example in 
the arterial intima in atherosclerosis, and are recognised in the kidney in damaged 
glomeruli (Moorhead 1991). Given the pivotal role of the monocyte/macrophage in 
modulating tissue injury and the diverse biological activities of these cells, these 
findings may have important implications in the context of glomerular disease as 
supported by the demonstration of both PPAR-γ and scavenger receptor expression in 
inflamed human kidney sections. Thus, matrix-mediated activation may influence the 
behaviour of monocytes that infiltrate the glomerular mesangium and thereby potentially 
modify the outcome of an inflammatory process. 
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It is recognised that the phenotypic state adopted by a tissue macrophage is 
influenced by the activation signals that naïve monocytes receive and that broadly, two 
distinct activated phenotypes can be identified. The classical activation pathway results 
from exposure to Th-1 type cytokines such as TNF-α, IL-1β and IL-6 and results in a 
macrophage with pro-inflammatory properties, capable of further generation of pro-
inflammatory cytokines and the degradation of normal and abnormal matrix components 
(Erwig, Kluth et al. 2001). Classically activated cells also possess the ability to take up 
modified lipoproteins, potentially resulting in the formation of lipid-laden foam cells. In 
contrast, the alternative activation pathway induced by Th-2 type cytokines such as IL-4 
and IL-13 produces a macrophage that generates anti-inflammatory cytokines, 
suppresses the synthesis of pro-inflammatory cytokines and is resistant to re-activation, 
thus being responsible for co-ordinating resolution of an inflammatory process (Duffield 
2003). Taken together with the previous chapter, which demonstrated that incubation of 
monocytes with mesangial cell matrix stimulates secretion of the pro-inflammatory 
cytokines IL-6, IL-1β and TNF-α as well as matrix-degrading metalloproteinases, it 
seems reasonable to conclude that mesangial cell matrix activates macrophages via the 
classical pathway.  
In late 2005 the Th-1 type and Th-2 paradigm was further simplified. Monocytes 
primed by Th-1 type cytokines, which promote differentiation into proatherogenic 
‘Classical’ macrophages were termed M1 macrophages, while those primed by Th-2 
type cytokines, which lead to  an “Alternative” anti-inflammatory macrophage 
phenotype, were termed M2 macrophages (Mantovani, Sica et al. 2005). Functional 
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polarization of macrophages into M1 or M2 cells was deemed as more operationally 
useful and provided a simplified conceptual framework describing the plasticity of 
mononuclear phagocytes (Mantovani, Sica et al. 2004). Genetic approaches have begun 
to shed new light on mechanisms underlying macrophage differentiation and attempts to 
dissect the actual in vivo significance of their polarization are currently being 
investigated (Rauh, Ho et al. 2005; Biswas and Mantovani 2010). 
These findings are highly relevant to the fate of monocytes that undergo 
transmigration to become tissue macrophages, but not to cells that undergo reverse-
transmigration since they adopt the phenotype of an immature or mature dendritic cell 
(depending on the absence or presence of inflammatory stimuli respectively) (Randolph, 
Beaulieu et al. 1998).  
Other macrophage-specific markers which have been previously explored by my 
colleagues included CD69 and the HLA-DR antigens (Chana, Martin et al. 2003). 
However it was discovered that both markers were expressed at low levels on THP-1 
monocytes with no significant up-regulation occurring following stimulation with PMA, 
an accepted and potent activator of monocytes. Other investigators have observed that 
HLA-DR expression varies with the source of the macrophage, such that 15% of 
peritoneal macrophages express the antigen compared to 50% of spleen and thymus-
derived cells (Lewis, Norris et al. 1990). Another potential candidate was Mac-1, a 
member of the β2 integrin family also known as CD11b/CD18, however, this cell 
surface adhesion receptor proved not to be specific to macrophages and was also 
expressed at low levels by freshly isolated monocytes as demonstrated by other workers 
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(Miller, Bainton et al. 1987). PPAR-γ expression proved to be a more useful indicator 
since this intracellular receptor showed very low levels of expression in monocytes, but 
is strongly induced during their differentiation into mature macrophages, suggesting that 
it may be involved in the differentiation process. In addition, PPAR-γ has been 
implicated in the modulation of several macrophage functions including the regulation 
of pro-inflammatory activities and stimulation of ox-LDL uptake further strengthening 
the use of this factor as a macrophage marker (Moore, Fitzgerald et al. 2001). PPAR-γ is 
also abundantly expressed in lesions such as atherosclerotic plaques where formation of 
foam cells is observed (Tontonoz, Nagy et al. 1998). It should be emphasised that 
PPAR-γ was used simply as a macrophage marker in these studies and that ligand-
induced activation of this receptor was not examined. It seems likely that other 
signalling pathways are activated by matrix-monocyte interactions, particularly since 
PPAR-γ activation does not explain the increase in cytokine production that has 
previously been reported (Chana, Martin et al. 2003).  
Scavenger receptor-A is a macrophage-specific cell surface protein that 
specifically binds and internalises oxidised and chemically modified LDL particles, 
similar to the class B scavenger receptor; CD36, which also bind modified forms of LDL 
(Brown, Basu et al. 1980). Scavenger receptor expression is restricted to macrophages 
thereby providing a reliable marker for the purpose of these studies. Scavenger receptor-
A has been implicated in mediating a variety macrophage functions, including 
intracellular signalling, endocytosis, adhesion and phagocytosis. Unlike uptake of native 
LDL via the LDL receptor, which is tightly controlled, scavenger receptor-A mediated 
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uptake of modified lipoprotein is not regulated by intracellular cholesterol levels and can 
therefore potentially lead to intracellular cholesterol accumulation and the formation of 
foam cells (Gough, Greaves et al. 1999). The class B scavenger receptor CD36 has also 
been implicated in the process of lipid accumulation in macrophages and serves as an 
adhesion receptor on macrophages for matrix components such as collagen and 
thrombospondin (Tandon, Kralisz et al. 1989). 
In keeping with the changes in lipoprotein receptor expression observed, matrix-
activated monocytes accumulated intracellular lipid when incubated with Ac-LDL, a 
synthetic scavenger receptor ligand, as demonstrated by intracellular Oil Red O staining. 
This phagocytic capacity was further confirmed by flow cytometry of matrix-activated 
monocytes exposed to Dil-labelled Ac-LDL. Uptake of Ac-LDL was shown to be 
specific, since it could be inhibited by addition of an excess of unlabelled acetylated 
lipoprotein, thus confirming receptor involvement. Induction of phagocytic activity was 
also observed following PMA-mediated activation, but not when an irrelevant protein 
(BSA) was added.  
Lipoproteins, including LDL, infiltrate the normal mesangium and are found 
deposited in diseased glomeruli (Wheeler and Chana 1993). Having previously shown 
that mesangial cells oxidise LDL in vitro (Wheeler, Chana et al. 1994), It has been 
demonstrated here that exposure of LDL to mesangial matrix has a similar effect. Thus, 
not only does matrix exposure induce a phagocytic macrophage phenotype in 
monocytes, but also converts LDL to an appropriate scavenger receptor ligand thereby 
potentially contributing to the development of foam cells. The mechanisms by which 
matrix promotes LDL oxidation were not explored but may involve entrapment of 
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lipoprotein by glycosaminoglycans, thereby rendering particles more susceptible to the 
effects of reactive oxidative species (Abuja 2002). 
In conclusion, mesangial matrix has the capacity to convert monocytes to 
macrophages displaying characteristics associated with a classically activated 
phenotype. By inducing macrophage scavenger receptor expression and converting LDL 
to an oxidised product, matrix may also play a key role in the formation of foam cells 
within the glomerular mesangium. The impact of changes in matrix composition on 
these interactions and the potential for such changes to modify the outcome of an 
inflammatory process within the glomerulus warrant further investigation. 
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CHAPTER 5 
GENERAL DISCUSSION AND CONCLUSION 
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5.1. RESEARCH QUESTIONS ADDRESSED IN THIS THESIS 
 
Infiltration of mononuclear cells into the mesangium and their differentiation are 
recognized as an early event in many diseases that ultimately lead to chronic kidney 
failure. A variety of factors are likely to play key roles in orchestrating monocyte influx 
and in determining the phenotype that the infiltrating monocytes ultimately adopt. In 
particular, monocyte interactions with components of mesangial matrix may play a key 
role in these processes. 
The work presented in this thesis set out to dissect the nature of the interaction 
between monocytes and mesangial cell matrix and the resulting changes in monocyte 
phenotype. A representative matrix protein component, namely Fibronectin, which is up-
regulated when mesangial cells are exposed to TGF-β and TNF-α (Chana and Wheeler 
1999) was used to conduct matrix binding and blocking studies to examine the extent to 
which matrix exposure modified cytokine, MMP and TIMP production by monocytes. 
Whole matrix, as well as other matrix protein components namely Collagen type IV and 
Laminin were also examined for their effects on cytokine production. 
To address the extent of monocyte differentiation into macrophages upon 
exposure to mesangial cell matrix, one challenge was the identification of a suitably 
robust marker of monocyte to macrophage conversion. After a thorough literature search 
three reliable macrophage specific markers were studied: a) PPAR−γ, b) CD36 and c) 
Scavenger receptor class-A.  
Finally since LDL may play a central role in the pathogenesis of 
glomerulosclerosis it was assessed whether this lipoprotein might become oxidized in 
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the mesangium by exposure to matrix, thereby becoming a ligand for uptake via 
macrophage scavenger receptors and promoting foam cell formation.  
 
5.2. LIMITATIONS OF THE EXPERIMENTAL WORK  
 
5.2.1. Monocyte Binding Studies 
 
From earlier experiments by our group (Chana and Wheeler 1999) it has 
demonstrated that exposure of mesangial cells to LDL stimulates the production of the 
monocyte chemoattractant MCP-1, indicating that the presence of LDL within the 
injured glomerular mesangium might promote monocyte accumulation. It was also 
demonstrated that LDL increases the synthesis of the matrix component fibronectin by 
mesangial cells, thus providing an additional factor by which monocytes might be 
retained. In the experiments described in this thesis, this work was taken forward by 
examining ligand-integrin interactions involving fibronectin and monocytes. One 
criticism is that most of these experiments were based on a monocyte cell line. However, 
although U937 monocytes were used in the earlier experiments, these data were 
strengthened by using the same blocking antibodies in experiments using whole matrix 
and human PBMCs, and also found a decrease in monocyte adhesion to matrix through 
the VLA-4 and VLA-5 integrin receptors. When examining the resulting secretory 
behaviour of monocytes upon binding to whole matrix and individual matrix proteins 
PBMCs were also used in some of these experiments. It can therefore be accepted that 
the U937 cell line provided an appropriate model on which to base these experiments. 
 131
Ideally it would have been possible to extract individual component proteins of 
mesangial matrix. However this would have required huge amounts of matrix and a 
complex extraction process which would not have guaranteed pure protein components. 
The other option was to qualitatively and quantitatively define the components of 
mesangial cell matrix. Although attempts to do this were investigated, it was not a 
feasible option given the focus of these investigations. Instead, a decision to use an equal 
volume of the three major matrix proteins was taken, namely Collagen Type IV, 
Fibronectin and Laminin and make a comparison with whole matrix when looking at 
changes in inflammatory cytokine secretory behaviour and activation of MMP-9 and 
TIMPs by PBMCs.  
Since experiments involving cytokine and MMP secretion and TIMP activation 
were performed at a single time-point of 24 hours, the possibility that at later time 
points, matrix activated macrophages lose their pro-inflammatory capacity, and take on 
the alternatively activated anti-inflammatory phenotype, cannot be excluded. In vivo, 
both cell phenotypes are likely to be present in inflamed tissue and the balance between 
them may be critical in determining the extent of subsequent fibrosis. It is also possible 
that a classically-activated macrophage programmed by exposure to matrix does not 
respond to the signals usually associated with the alternative activation pathway, 
potentially resulting in an uncontrolled inflammatory response with limited subsequent 
tissue repair (Duffield 2003). Further time-points up to 7 days may prove useful in 
answering this question. 
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5.2.2. Monocyte Activation Studies 
 
When designing these experiments one challenge was the identification of a 
suitably robust marker of monocyte to macrophage conversion. The three macrophage 
specific markers chosen were a) PPAR-γ, b) CD36 and c) Scavenger receptor class-A. 
MAC-1 was considered but was abandoned due to there being low levels of expression 
on freshly isolated monocytes, as also demonstrated by others (Bainton, Miller et al. 
1987; Cifarelli, Libman et al. 2007; Yakubenko, Belevych et al. 2008).  
The observed changes in macrophage specific markers following matrix 
interaction were reproduced using the THP-1 monocyte cell line supplied by two 
companies (ECACC and ATCC) both of which claim that these cells differentiate into 
macrophages. In addition, a number of published studies appear to support the 
differentiation of this cell line (Tsuchiya, Yamabe et al. 1980; Kritharides, Christian et 
al. 1998; Kim, Studer et al. 2008). Taking into account the available literature and 
discussions with experts working in the field of inflammation, it can be accepted that 
these cells provided a reasonable model for these experiments. 
To further validate the model, studies comparing the response of human 
peripheral blood monocytes and THP-1 cells to mesangial matrix assessing the 
production of inflammatory cytokines and MMP-9 were performed. These studies show 
almost identical patterns of induction suggesting that the two cell types show similar 
responsiveness. Furthermore, previous work by our group has demonstrated similarities 
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between monocyte cell lines and cells isolated from peripheral blood in terms of surface 
markers and binding characteristics (Wheeler, Chana et al. 1994).  
 
5.2.3. Disease Specific Matrix Modification 
 
Matrix elaborated by healthy mesangial cells were used, however this did not 
take account of the fact that disease-specific matrix modification may influence 
monocyte activation, since there is strong evidence to suggest that monocyte-
macrophage differentiation is influenced by the nature of the matrix proteins (Laouar, 
Collart et al. 1999) For example, matrix glycation that occurs in diabetes mellitus 
influences the balance between matrix synthesis and degradation by mesangial cells, 
promoting accumulation (Schleicher and Olgemoller 1992) and may also affect 
monocyte to macrophage differentiation. Indeed many studies have shown that non-
enzymatically glycated matrix occurring in diabetes influences monocyte to macrophage 
differentiation (Jacob, Shastry et al. 2001; Min, Lyons et al. 2009). A key matrix protein, 
collagen type 1 when non-enzymatically glycated was shown to accelerate monocyte to 
macrophage differentiation, leading to foam cell formation upon interaction with 
oxidised LDL (Jacob, Shastry et al. 2001). Since mesangial cell matrix may be 
particularly prone to glycation as a result of its prolonged lifespan, an extension to this 
work would be to investigate various matrix modifications on monocyte differentiation 
such as non-enzymatic glycation. 
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5.2.4. Mesangial Cell Matrix Sequesters Cytokines and Growth Factors 
 
The possibility that these results are at least in part explained by retention of low 
concentrations of cytokines within the matrix material cannot be ruled out. More 
detailed experiments investigating the ability of matrix to sequester growth factors and 
cytokines would be the next logical step in investigating the effects on monocyte 
behaviour. For example investigating the effects of matrix impregnated with TGF-β, 
matrix has been shown to sequester this growth factor and it has been shown to play an 
important role in matrix production. (Gambaro and Baggio 1998).  
 
5.2.5. Scavenger receptor: Protein Level Expression 
 
Experiments were limited to examining the expression of scavenger receptors at 
the message level without going on to provide protein expression data as was the case 
with PPAR-γ expression. However, up-regulation of functional scavenger receptors in 
the lipoprotein uptake studies was demonstrated and it is unlikely that further extending 
these studies to examine scavenger receptor expression at the protein level would have 
changed the conclusions.  
 
5.3. IMPLICATIONS OF MAJOR FINDINGS 
 
The work presented in this thesis help us to better understand how matrix 
components contribute to changes in monocyte phenotype. Chapter 3 demonstrates that 
mesangial matrix plays a key role in the immobilization and activation of monocytes 
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within the glomerulus. These results would also suggest that accumulation of fibronectin 
enhances metalloproteinase production, without increased inhibitor activity, a situation 
that is likely to promote matrix degradation.  
In Chapter 4, initial findings were further strengthened by demonstrating that 
mesangial matrix has the capacity to convert monocytes to macrophages displaying 
characteristics associated with a classically activated phenotype. Since lipoproteins, 
including LDL, infiltrate the normal mesangium and are found deposited in diseased 
glomeruli (Wheeler and Chana 1993) mesangial cell matrix may play a key role in the 
formation of foam cells within the glomerular mesangium through its capacity to oxidise 
LDL as well as stimulate monocyte to macrophage differentiation. 
Thus it has been demonstrated that interactions between mesangial matrix 
components and infiltrating monocytes may play a key role in the progression of 
glomerular injury.  
 
5.4. POTENTIAL THERAPEUTIC IMPLICATIONS 
 
 Interactions between adhesion molecules and infiltrating macrophages have been 
successfully blocked and could serve as targets for therapeutic interventions (Adler and 
Brady 1999; Allen, McHale et al. 1999; Chana and Wheeler 1999; Cook, Khan et al. 
2002). The humanized version of this anti-α4 monoclonal antibody known as 
Natalizumab has been used successfully in multicenter double-blind controlled studies in 
Crohn's disease and multiple sclerosis (Ghosh, Goldin et al. 2003; Miller, Khan et al. 
2003; Miller, Soon et al. 2007; Targan, Feagan et al. 2007). Despite there being adverse 
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reactions in some patients to this drug it was given approval by the FDA as its clinical 
benefits outweighed the risks involved (Ransohoff 2010; Steiner 2010). It would be interesting 
to see the effects of this drug on patients suffering from glomerulosclerosis. 
The beta-2 integrins include CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-
1/Complement receptor 3). A humanized monoclonal antibody to CD18 known as 
Efalizumab, which blocks CD11a/CD18 and CD11b/CD18 has been reported to reduce 
infiltrating leukocytes and improve vasculitic ulcers in patients with systemic vasculitis 
(Lockwood, Elliott et al. 1999), however ten years on Efalizumab has been withdrawn 
from the market as it was associated in some cases with fatal brain infections (Major 
2010). Inhibition of monocyte responses by blockade of these signalling pathways 
represents a potential target for therapeutic intervention in human glomerular disease. 
 
5.5. CONCLUSION 
 
In summary, enhanced monocyte adhesion to mesangial cell matrix results in 
monocyte retention, activation and differentiation within the glomerular mesangium. In 
the presence of LDL, macrophages are likely to accumulate lipid to form foam cells. 
Inhibition of monocyte-matrix interactions represents a potential therapeutic intervention 
that may prove protective in the setting of kidney disease. . 
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